CN1479629A - 干扰VEGF/VEGF和血管生成素/Tie受体功能的组合和组合物以及它们的用途(II) - Google Patents
干扰VEGF/VEGF和血管生成素/Tie受体功能的组合和组合物以及它们的用途(II) Download PDFInfo
- Publication number
- CN1479629A CN1479629A CNA018115837A CN01811583A CN1479629A CN 1479629 A CN1479629 A CN 1479629A CN A018115837 A CNA018115837 A CN A018115837A CN 01811583 A CN01811583 A CN 01811583A CN 1479629 A CN1479629 A CN 1479629A
- Authority
- CN
- China
- Prior art keywords
- compound
- vegf
- pharmaceutical composition
- group
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明描述了干扰血管内皮生长因子(VEGF)/VEGF受体系统生物活性的物质(化合物I)和干扰血管生成素(Angiopoietin)/Tie受体系统生物功能的物质(化合物II)的组合,所述组合用于抑制血管形成和治疗癌症。
Description
本发明提供干扰血管内皮生长因子(VEGF)/VEGF受体系统生物活性的物质(化合物I)和干扰血管生成素(Angiopoietin)/Tie受体系统生物功能的物质(化合物II)的组合,所述组合用于抑制血管形成和治疗癌症。
特异性调节内皮细胞功能的蛋白质配体和受体酪氨酸激酶实质上与生理血管发生以及与疾病相关的血管发生有关。这些配体/受体系统包括血管内皮生长因子(VEGF)和血管生成素(Ang)家族,以及它们的受体,VEGF受体家族和具有免疫球蛋白样及表皮生长因子同源域(Tie)的酪氨酸激酶家族。受体酪氨酸激酶两个家族的成员主要在内皮细胞上表达。VEGF受体家族包括Flt1(VEGF-R1)、Flk1/KDR(VEGF-R2)和Flot4(VEGF-R3)。这些受体被VEGF相关生长因子的成员所识别,因为Flt1的配体是VEGF和胎盘生长因子(PIGF),而Flk1/KDR与VEGF、VEGF-C和VEGF-D结合,并且Flt4的配体是VEGF-C和VEGF-D(Nicosia,Am.J.Pathol.153,11-16,1998)。内皮细胞特异性受体酪氨酸激酶的第二个家族由Tie1和Tie2代表(也称作Tek)。虽然Tie1仍是孤儿受体,但是已经发现了Tie2的三个分泌的糖蛋白配体Ang1、Ang2和Ang3/Ang4(Davis等,Cell87,1161-1169,1996;Maisonpierre等,Science 277,55-60,1997;Valenzuela等,Proc.Natl.Acad.Sci.USA 96,1904-1909,1999;专利:US5,521,073、US 5,650,490、US 5,814,464)。
VEGF及其受体在血管发育期间的关键作用在对靶向基因失活的研究方面得以例证。甚至VEGF基因的杂合破裂都导致血管形成的致命缺陷(Carmeliet等,Nature 380,435-439,1996;Ferrara等,Nature 380,439-442,1996)。在FIt1或Flk1/KDR基因中携带纯合破裂的小鼠在妊娠中期死于急性血管缺损。但是,表型的独特之处在于Flk1/KDR剔除的小鼠缺乏内皮细胞和发育的造血系统(Shalaby等,Nature 376,62-66,1995),然而Flt1缺乏的小鼠具有正常的造血祖细胞和内皮细胞,却不能组装成功能性血管(Fong等,376,66-70,1995)。Flt4基因广泛的胚胎表达仅限于成体中的淋巴管,其破裂表明在心血管系统早期发育期间,Flt4对初始血管网络重构并成熟为大血管的重要作用(Dumont等,Science 282,946-949,1998)。与成体中Flt4的淋巴表达一致,VEGF-C在转基因小鼠皮肤中的过度表达导致淋巴,而不是血管的内皮增生和血管扩大(Jeltsch等,Science 276,1423-1425,1997)。此外,据报道VEGF-C在小鼠角膜和小鸡胚胎绒膜尿囊膜血管发生模型中诱导新血管形成(Cao等,Proc.Natl.Acad.Sci.USA 95,14389-14394,1998)。
也已经发现第二类内皮细胞特异性受体酪氨酸激酶在脉管系统的形成和完整性方面是非常有关的。Tie1缺乏的小鼠死于水肿和出血,其原因是微血管系统内皮细胞的差结构完整性(Sato等,Nature376,7074,1995;Rodewald & Sato,Oncogene 12,397-404,1996)。Tie2剔除的表型的特征在于缺乏分支网络并且缺乏外周内皮支持细胞的未成熟血管(Sato等,Nature 376,70-74,1995;Dumont等,GenesDev.8,1897-1909,1994)。Tie2配体Ang1的靶向失活,以及抑制配体Ang2的过度表达导致与Tie2剔除相似的表型(Maisonpierre等,Science 277,55-60,1997;Suri等,cell 87,1171-1180)。相反,在Ang1的转基因过度表达之后立即观察到增加的血管形成(Suri等,Science 282,468-471,1998;Thurstonen等,Science 286,2511-2514,1999)。
对黄体发育中血管源性生长因子表达的研究的结果(Maisonpierre等,Science 277,55-60,1997;Goede等.Lab.Invest.78,1385-1394,1998),对视网膜中血管成熟的研究的结果(Alon等,NatureMed.1,1024-1028,1995;Benjamin等,Development 125,1591-1598,1998),以及对Tie2、Ang1和Ang2的基因靶向和转基因试验的结果提示血管生成素/Tie受体系统在介导内皮细胞和周围周细胞或平滑肌细胞之间相互作用中的重要作用。由外周内皮细胞(periendothelialcell)表达并且似乎基本上在成体内表达的Ang1被认为使存在的成熟血管稳定化。Ang2,在血管发育位置由内皮细胞表达的Ang1的天然拮抗剂,似乎介导内皮-外周内皮细胞接触的松动,从而允许血管重构并在诸如VEGF的血管发生引发剂的协作下发育,或者在缺乏VEGF时血管退化(Hanahan,Science 277,48-50,1997)。
在与异常的新血管形成相关的病态集(pathological setting)中已经观察到血管源性生长因子及其受体的升高的表达。大多数实体瘤表达高水平的VEGF,且VEGF受体主要出现在恶性组织周围的血管或贯穿恶性组织的血管的内皮细胞中(Plate等,Cancer Res.53,5822-5827,1993)。通过VEGF-中和抗体干扰VEGF/VEGF受体系统(Kim等,Nature 362,841-844,1993),显性阴性VEGF受体变体的反转录病毒表达(Millauer等,Nature 367,576-579,1994),重组VEGF-中和受体变体(Goldman等,Proc.Natl.Acad.Sci.USA 95,8795-8800,1998),或者VEGF受体酪氨酸激酶的小分子抑制剂(Fong等,Cancer Res.59,99-106,1999;Wedge等,Cancer Res.60,970-975,2000;Wood等,Cancer Res.60,2178-2189,2000),或者通过VEGF/VEGF受体系统靶向细胞毒试剂(Arora等,Cancer Res.59,183-188,1999;EP 0696456A2)导致降低肿瘤生长和肿瘤血管形成的减少。然而,尽管通过干扰VEGF/VEGF受体系统使许多肿瘤得以抑制,但其他一些肿瘤不受影响(Millauer等,Cancer Res.56,1615-1620,1996)。人肿瘤和实验肿瘤异种移植物含有大量尚未补充外周内皮细胞的未成熟血管。未成熟血管在缓慢生长的前列腺癌外周内皮细胞的未成熟血管。未成熟血管在缓慢生长的前列腺癌中所占比例在40%的范围内,在快速生长的成胶质细胞瘤中所占比例在90%的范围内。在C6成胶质细胞瘤异种移植物模型中,通过减量调节VEGF转基因表达而退缩VEGF之后立即观察到未成熟肿瘤血管的选择性闭塞。这一结果与VEGF作为内皮细胞存活因子的功能一致。类似地,作为雄激素消融疗法结果的人前列腺癌关闭VEGF表达导致缺乏外周内皮细胞覆盖的血管中内皮细胞的选择性凋亡。相反,抵抗VEGF退缩的血管部分显示外周内皮细胞覆盖(Benjamin等,J.Clin.Invest.103,159-165,1999)。
Tie受体在转移性黑色素瘤内皮(Kaipainen等,Cancer Res.54,6571-6577,1994)、乳腺癌(salve等,Br.J.Cancer 74,69-72,1996)和显性阴性VEGF受体存在下生长的肿瘤异种移植物(Millauer等,Cancer Res.56,1615-1620,1996)中的升高的表达,以及Flt4受体在淋巴和乳腺癌周围的淋巴管内皮中(Jussila等,Cancer Res.58,1599-1604,1998)、VEGF-C在各种人肿瘤样品中(salve等,Am.J.Pathol.153,103-108,1998)的升高的表达的观察结果提示这些内皮特异性生长因子和受体作为驱动肿瘤新血管形成的候选可选途径。在早期肿瘤中Ang2表达的高增量调节已经被解释为针对发育中的肿瘤对现有血管的初始补选(initial cooption)的宿主防御机理。在缺乏VEGF的情况下,补选的血管经历消退,导致肿瘤中心内的坏死。相反,升高的Ang2表达协同VEGF表达的缺氧增量调节拯救并支持肿瘤边缘的血管形成和肿瘤生长(Holash等,Science 284,1994-1998,1999;Holash等,Oncogene 18,5356-5362,1999)。
已证明通过由胞外配体结合域组成的血管生成素-中和Tie2变体干扰Tie2受体功能导致实验肿瘤的生长和血管形生的抑制(Lin等,J.Clin.Invest.103,159-165,1999;Lin等.Proc.Natl.Acad.Sci.USA 95,8829-8834,1998;Siemeister等,Cancer Res.59,3185-3191,1999)。比较通过相应的胞外受体域的旁分泌表达干扰内皮特异性受体酪氨酸激酶对相同细胞背景的影响,证明VEGF受体系统和Tie2受体系统封闭后各自的肿瘤生长的抑制(Siemeister等,Cancer Res.59,3185-3191,1999)。
已知用各种方法抑制VEGF/VEGF受体系统仅导致大多数实验肿瘤生长的减慢(Millauer等,Nature 367,576-579,1994;Kim等,Nature 362,841-844,1993;Millauer等,Cancer Res.56,1615-1620,1996;Goldman等,Proc.Natl.Acad.Sci.USA 95,8795-8800,1998;Fong等,Cancer Res.59,99-106,1999;Wedge等,Cancer Res.60,970-975,2000;Wood等,Cancer Res.60,2178-2189,2000;Siemeister等,Cancer Res.59,3185-3191,1999)。甚至通过治疗剂量增加也实现治疗效果的高峰水平(Kim等,Nature 362,841-844,1993;Wood等Cancer Res.60,2178-2189,2000)。类似的结果可以在干扰血管生成素/Tie2受体系统时观察到(Lin等,J.Clin.Invest.103,159-165,1999;Lin等,Proc.Natl. Acad.Sci.USA 95,8829-8834,1998;Siemeister等,Cancer Res.59,3185-3191,1999)。
然而,仍非常需要增强抗血管发生化合物治疗功效的方法。
在寻找增强抗血管发生化合物治疗功效的方法时,在组合抑制VEGF/VEGF受体系统和干扰血管生成素/Tie受体系统生物功能后,意外地观察到优越的抗肿瘤作用。所观察到的优越作用的作用模式可能是干扰血管生成素/Tie受体系统的生物功能破坏现有成熟肿瘤血管的内皮细胞-外周内皮细胞的相互作用的稳定性,从而使内皮对针对VEGF/VEGF受体系统的化合物变得敏感。
基于这一意外的发现,本发明提供功能性干扰VEGF/VEGF受体系统和功能性干扰血管生成素/Tie受体系统的组合,其用于抑制血管形成和肿瘤生长。
本发明的药物组合物由以下两种成分组成:化合物I抑制一种或几种VEGF/VEGF受体系统的生物活性,或者化合物I由通过VEGF/VEGF受体系统的识别而靶向于内皮的细胞毒试剂组成。化合物II干扰一种或几种血管生成素/Tie受体系统的生物功能,或者化合物II由通过血管生成素/Tie受体系统的识别而靶向于内皮的细胞毒试剂组成。或者,化合物I抑制一种或几种VEGF/VEGF受体系统的生物功能或血管生成素/Tie受体系统的生物活性,而化合物II由通过一种或几种VEGF/VEGF受体系统的识别或血管生成素/Tie受体系统的识别而靶向于内皮的细胞毒试剂组成。可以通过以下途径进行VEGF/VEGF受体系统和血管生成素/Tie受体系统的生物活性的靶向或调节:
a)抑制受体酪氨酸激酶活性的化合物;
b)抑制配体结合于受体的化合物;
c)抑制受体的胞内信号途径激活的化合物;
d)抑制或刺激VEGF或Tie受体系统的配体或受体表达的化
合物;
e)输运系统,如抗体、配体、高亲和性结合寡核苷酸或寡肽,
或脂质体,它们通过VEGF/VEGF受体系统或血管生成素
/Tie受体系统的识别使细胞毒试剂或凝固作用诱导试剂靶
向于内皮;
f)输运系统,如抗体、配体、高亲和性结合寡核苷酸或寡肽,
或脂质体,它们靶向于内皮并诱导坏死或凋亡。
本发明的组合物包含的化合物可以是小分子量的物质、寡核苷酸、寡肽、重组蛋白、抗体,或者它们的缀合物或融合蛋白。抑制剂的实例是通过与催化位点结合并占据催化位点使受体酪氨酸激酶失活从而降低受体生物活性的小分子量分子。激酶抑制剂在本领域是公知的(Sugen:SU5416,SU6668;Fong等,(1999),Cancer Res.59,99-106;Vajkoczy等,Proc.Am.Associ.Cancer Res.San Francisco(2000),Abstract ID 3612;Zeneca:ZD4190,ZD6474;Wedge等,(2000),Cancer Res.60,970-975;Parke-Davis PD0173073,PD0173074;Johnson等,Proc.Am.Associ.Cancer Res.,San Franzisco(2000),Abstract ID 3614;Dimitroff等,(1999),Invest.New Drugs 17,121-135)。拮抗剂的实例是与配体结合从而阻止配体激活受体的重组蛋白或抗体。拮抗剂的另一个实例是与受体结合从而阻止受体激活的抗体。表达调节剂的实例是控制配体或受体表达的反义RNA或核酶。靶向细胞毒试剂的实例是配体和细菌或植物毒素如假单胞菌外毒素A、白喉毒素或蓖麻毒蛋白毒素的融合蛋白。靶向凝固作用诱导试剂的实例是单链抗体和组织因子的缀合物。Genentech(rhuMAbVEGF)和Presta等,(1997),Cancer Res.57,4593-4599描述了配体结合抑制剂,如本领域公知的中和抗体。配体结合受体域在下列文献中描述:Kendall & Thomas(1993),Proc.Natl.Acad.Sci.,U.S.A.90,10705-10709;Goldman等,(1998);Proc.Natl.Acad.Sci.,U.S.A.95,8795-8800;以及Lin等,(1997),J.Clin.Invest.100,2072-2078。另外,显性阴性受体在Millauer等,(1994),Nature 367,567-579中描述。
Imclone(c-p1C11,US 5,874,542)已经描述了受体封闭性抗体。另外,拮抗配体突变体也是公知的(Siemeister等,(1998),Proc.Natl.Acad.Sci.,U.S.A.95,4625-4629)。高亲和性配体或受体结合寡核苷酸已经在NeXstar(NX-244)和Drolet等,(1996),Nat.Biotech 14,1021-1025中描述。另外,小分子和肽也已经得到描述。
表达调节剂已被描述为反义寡核苷酸和核酶(RPI,AngiozymeTM),参见RPI主页)。
输运/靶向系统的实例已被描述为配体/抗体-毒素-融合-蛋白或缀合物(Arora等,(1999),Cancer Res.59,183-188和Olson等,(1997),Int.J.Cancer 73,865-870);被描述为脂质体的内皮细胞靶向(Spragg等,(1997),Prog.Natl.Acad.Sci,U.S.A94,8795-8800;以及被描述为内皮细胞靶向加凝固作用诱导(Ran等,(1998),Cancer Res.58,4646-4653)。
举例来说,抑制受体酪氨酸激酶活性的小分子是通式I的分子:式中r为0至2,n为0至2;R3和R4 a)彼此独立地代表低级烷基;
c)一起形成通式III的桥,其中环成员T1、T2、T3、T4中的一个或两个代表氮,其它代表CH,并且通过原子T1和T4连接;G代表C1-C6烷基、C2-C6亚烷基或C2-C6亚烯基;或者被酰氧基或羟基取代的C2-C6亚烷基或C3-C6亚烯基;-CH2-O-、-CH2-S-、-CH2-NH-、-CH2-O-CH2-、-CH2-S-CH2-、-CH2-NH-CH2、氧(-O-)、硫(-S-)或亚氨基(-NH-);A、B、D、E和T彼此独立地代表N或CH,条件是这些取代基中不超过三个代表N;Q代表低级烷基、低级烷氧基或卤素;R1和R2彼此独立地代表H或低级烷基;X代表亚氨基、氧或硫;Y代表氢、未取代或取代的芳基、杂芳基,或者未取代或取代的环烷基;且Z代表氨基、单或二取代的氨基、卤素、烷基、取代的烷基、羟基、醚化或酯化的羟基、硝基、氰基、羧基、酯化的羧基、烷酰基、氨基甲酰基、N-单取代或N,N-二取代的氨基甲酰基、脒基、胍基、巯基、硫代、苯硫基、苯基-低级烷基-硫、烷基-苯基-硫、苯基亚磺酰基、苯基-低级烷基-亚磺酰基、烷基苯基亚磺酰基、苯基磺酰基、苯基-低级烷-磺酰基,或者烷基苯基磺酰基,但是,如果存在多于一个其余的Z(m≥2),取代基Z彼此相同或不同,而且其中箭头表示的键是单键或双键;或者所述化合物的N氧化物,其中一个或多个N原子携带氧原子;或者是它们的盐。
优选的盐是有机酸盐,尤其是琥珀酸盐。
这些化合物可以优选地在本发明的药物组合物中用作化合物I或化合物II。
举例来说,分别阻止酪氨酸磷酸化,或阻止持续血管发生从而导致阻止肿瘤生长和肿瘤扩散的化合物是通式IV的蒽酸(anthranylacid)衍生物:式中A代表=NR2基团;W代表氧、硫、两个氢原子或=NR8基团,Z代表=NR10基团,或=N-、-N(R10)-、(CH2)q-、支链或非支链C1-6烷基,或者是以下基团:或者A、Z和R1一起形成以下基团: 或
m、n和o为0至3,q为1至6,Ra、Rb、Rc、Rd、Re、Rf彼此独立地代表氢、C1-4烷基或=NR10基团,和/或Ra和/或Rb与Rc和/或Rd一起,或者Rc与Re和/或Rf一起形成键,或者Ra-Rf基团中多达两个与R1或R2形成每个多达三个碳原子的桥,X代表=NR9或=N-基团;Y代表-(CH2)p基团,p为整数1至4;R1代表未取代或任选地被一个或多个卤素取代的C1-6烷基,或任选地被一个或多个卤素取代的C1-6烷基或C1-6烷氧基,或者是未取代或取代的芳基或杂芳基;R2代表氢或C1-6烷基,或与Ra-Rf和Z或R1一起形成多达3个环原子的桥;R3代表单环或双环芳基或杂芳基,它们未被取代或任选地被一个或多个卤素、C1-6烷基、C1-6烷氧基或羟基取代;R4、R5、R6和R7彼此独立地代表氢、卤素或C1-6烷氧基、C1-6烷基或C1-6羧基烷基,它们未被取代或任选地被一个或多个卤素取代,或者R5和R6一起形成以下基团:R8、R9和R10彼此独立地代表氢或C1-6烷基,以及它们的异构体和盐。
这些化合物也可以优选地在本发明的药物组合物中用作化合物I或II。
-CF3、-N=C、
-CH3、-OCF3
这些化合物具有与上述化合物IV中提到的相同的性质,并且可以用于治疗血管发生疾病。
组合物包含单独的通式I、IV和V的化合物,或者它们的组合。
上述化合物也是在本发明的组合内要求保护的主题。
配体结合抑制剂的其他实例是肽和编码这些肽的DNA序列,它们用于治疗血管发生疾病。这些肽和DNA序列在序列表的Seq.IDNo.1至59中公开。已证明Seq.ID No.34和34a是所主要关心的。
因此,本发明要求保护的主题是以下药物组合物:
a)包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I调节一种或几种VEGF/VEGF受体系统的生物功能,所述化合物II调节一种或几种血管生成素/Tie受体系统的生物功能。
b)包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I通过一种或几种VEGF/VEGF受体系统靶向于内皮,所述化合物II调节一种或几种血管生成素/Tie受体系统的生物功能。
c)包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I调节一种或几种VEGF/VEGF受体系统的生物功能,或者调节一种或几种血管生成素/Tie受体系统的生物功能,所述化合物II靶向于内皮。
d)包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I调节一种或几种VEGF/VEGF受体系统的生物功能,所述化合物II通过一种或几种血管生成素/Tie受体系统靶向于内皮。
e)包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I通过一种或几种VEGF/VEGF受体系统靶向于内皮,所述化合物II通过一种或几种血管生成素/Tie受体系统靶向于内皮。
f)包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I调节一种或几种VEGF/VEGF受体系统的生物功能,所述化合物II通过一种或几种VEGF/VEGF受体系统靶向于内皮。
g)包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I调节一种或几种血管生成素/Tie受体系统的生物功能,所述化合物II通过一种或几种血管生成素/Tie受体系统靶向于内皮,以及
h)包含一种或几种试剂的药物组合物,所述试剂既干扰一种或几种VEGF/VEGF受体系统的功能,也干扰一种或几种血管生成素/Tie受体系统的功能。
对于顺序治疗施用,本发明的药物组合物可以同时或单独施用。
本发明的组合物包含至少下列化合物之一作为化合物I或作为化合物II:
a)抑制受体酪氨酸激酶活性的化合物;
b)抑制配体结合于受体的化合物;
c)抑制受体的胞内信号途径激活的化合物;
d)抑制或刺激VEGF或Tie受体系统的配体或受体表达的化
合物;
e)输运系统,如抗体、配体、高亲和性结合寡核苷酸或寡肽,
或脂质体,它们通过VEGF/VEGF受体系统或血管生成素
/Tie受体系统的识别使细胞毒试剂或凝固作用诱导试剂靶
向于内皮;
f)输运系统,如抗体、配体、高亲和性结合寡核苷酸或寡肽,
或脂质体,它们靶向于内皮并诱导坏死或凋亡。
这些组合物也是本发明要求保护的主题。
本发明要求保护的主题还有包含Seq.ID No.1-59中至少之一作为化合物I和/或II的药物组合物。最有价值的是根据权利要求,包含Seq.ID No.34a作为化合物I和/或II的药物组合物,以及包含sTie2、mAB 4301-42-35、scFv-tTF和/或L19 scFv-tTF缀合物至少之一作为化合物I和/或II的药物组合物。
本发明的进一步优选的主题是包含至少一种通式I、通式IV和/或通式V的小分子作为化合物I和/或II的药物组合物。
可以在本发明的组合物中用作化合物I或II的最优选的化合物是琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵。
因此,本发明要求保护的主题还有包含琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵、sTie2、mAB 4301-42-35、scFv-tTF和/或L19 scFv-tTF缀合物作为化合物I,以及琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵、sTie2、mAB 4301-42-35、scFv-tTF和/或L19scFv-tTF缀合物作为化合物II的药物组合物,条件是化合物I与化合物II不同,以及最优选的包含琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵作为化合物I,以及sTie2、mAB 4301-42-35、scFv-tTF和/或L19 scFv-tTF缀合物作为化合物II的药物组合物;包含mAB4301-42-35作为化合物I,以及sTie2和/或scFv-tTF缀合物作为化合物II的药物组合物;包含scFv-tTF缀合物作为化合物I,以及sTie2和/或mAB 4301-42-35作为化合物II的药物组合物;包含L19 scFv-tTF缀合物作为化合物I,以及sTie2作为化合物II的药物组合物。
上述小分子化合物、蛋白质和DNA表达蛋白可以单独或以配方形式作为治疗肿瘤、癌症、银屑病、关节炎如类风湿性关节炎、血管瘤、血管纤维瘤、眼病如糖尿病性视网膜病变、新生血管性青光眼、肾病如肾小球肾炎、糖尿病肾病、恶性肾硬化、血栓性微血管病综合征、移植排斥反应和肾小球病、纤维化疾病如硬变肝、肾小球膜细胞增生疾病、关节硬化(artheriosclerosis)和神经组织损伤的药物。
用本发明的组合治疗损伤的神经组织阻碍损伤位置瘢痕的快速形成。这样,在轴突彼此联系之前没有瘢痕形成。因此,神经连接的重建更容易。
此外,本发明的组合可以用于抑制患者中腹水形成。还可能抑制VEGF水肿。为了将本发明的组合用作药物,将化合物配方成药物组合物。所述配方除包含一种或几种活性化合物之外,还包含药学可接受的有机或无机惰性载体,如水、明胶、阿拉伯胶、乳糖、淀粉、硬脂酸镁、滑石粉、植物油、聚亚烷基二醇等。所述药物制剂可以以固体形式施用,如片剂、丸剂、栓剂、胶囊剂,或者可以以液体形式施用,如溶液、混悬剂或乳剂。
如果需要,该组合物另外含有添加剂,如防腐剂、稳定剂、洗涤剂或乳化剂,用于改变渗透压的盐和/或缓冲剂。
这些用途以及活性化合物的配方也是本发明要求保护的主题。
对于肠胃外施用,注射溶液或混悬剂尤其适合,尤其是多羟基乙氧基化蓖麻油中的活性化合物水溶液。
还可以使用添加剂作为载体,如棓酸盐或者动物或植物磷脂,以及它们的混合物,和脂质体或其成份。
对于口服施用,具有滑石粉和/或烃载体或粘合剂如乳糖、玉米或马铃薯淀粉的片剂、丸剂或胶囊剂尤其适合。口服施用还可以是任选地含有甜味剂的液体形式,如果汁。
活性物质的剂量依据化合物的施用、患者的年龄和体重,以及疾病的形式和病程而不同。
活性化合物的每日剂量是0.5-1000mg,特别是50-200mg。剂量可以每日一剂,或者每日两剂或多剂。
这些配方和施用形式也是本发明的一部分。
对VEGF/VEGF受体系统和血管生成素/Tie受体系统的组合功能性干扰可以同时进行,或者顺序进行以使对干扰一种配体/受体系统的生物响应与对第二种配体/受体系统的生物响应重叠。或者,对VEGF/VEGF受体系统或血管生成素/Tie受体系统的组合功能性干扰,以及通过VEGF/VEGF受体系统或通过血管生成素/Tie受体系统靶向细胞毒试剂可以同时进行,或者顺序进行以使对功能性干扰配体/受体系统的生物响应及时与细胞毒试剂的靶向重叠。
本发明还涉及功能性干扰VEGF/VEGF受体系统和血管生成素/Tie受体系统的物质,或者通过VEGF/VEGF受体系统和血管生成素/Tie受体系统而靶向的物质。
VEGF/VEGF受体系统包括配体VEGF-A、VEGF-B、VEGF-C、VEGF-D、PIGF,和受体酪氨酸激酶VEGF-R1(Flt1)、VEGF-R2(KDR/Flk1)、VEGF-R3(Flt4),以及它们的共同受体(即神经菌毛蛋白-1(neuropilin-1))。血管生成素/Tie受体系统包括Ang1、Ang2、Ang3/Ang4,和与Tie1或Tie2结合的与血管生成素相关的多肽,以及受体酪氨酸激酶Tie1和Tie2。
本发明的药物组合物可以用于医疗目的。举例来说,这些疾病是癌症、癌转移、包括视网膜病变和银屑病在内的血管发生。本发明的药物组合物可以口服施用、肠胃外施用,或者通过基因疗法而施用。
因此,本发明还涉及药物组合物用于生产药物的用途,所述药物用于治疗肿瘤、癌症、银屑病、关节炎如类风湿性关节炎、血管瘤、血管纤维瘤、眼病如糖尿病性视网膜病变、新生血管性青光眼、肾病如肾小球肾炎、糖尿病肾病、恶性肾硬化、血栓性微血管病综合征、移植排斥反应和肾小球病、纤维化疾病如硬变肝、肾小球膜细胞增生疾病、关节硬化、神经组织损伤、抑制患者中腹水形成和抑制VEGF水肿。
以下实施例证明所公开的本发明的可行性,但并不将本发明限制于所公开的实施例。
实施例1
在A375v人黑色素瘤异种移植物模型中证明了相对于单独干预模式而言,通过抑制VEGF A/VEGF受体系统和功能性干扰血管生成素/Tie2受体系统的组合在抑制肿瘤生长方面的优越作用。
使人黑色素瘤细胞系A375v被稳定转染,从而过度表达人Tie2受体酪氨酸激酶的胞外配体-中和域(sTie2;化合物II)(Siemeister等,Cancer Res.59,3185-3191,1999)。为了对照,用空表达载体稳定地转染A375v细胞(A375v/pCEP)。分别用1×106个转染的A375v/sTie2或A375v/pCEP肿瘤细胞皮下注射瑞士nulnu小鼠。用每日剂量为50mg/Kg的VEGF受体酪氨酸激酶抑制剂琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵治疗接受化合物I的动物达38天(Wood等,Cancer Res.60,2178-2189,2000)。各种治疗方式如表1所述。通过卡尺测量最大直径及其垂线来确定肿瘤生长。
表1
治疗方式 | ||
治疗组 | 琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵(化合物I) | sTie2(化合物II) |
组1:A375v/pCEP | - | - |
组2:A375v/pCEP | + | - |
组3:A375v/sTie2 | - | + |
组4:A375v/sTie2 | + | + |
源于A375v/pCEP对照细胞的肿瘤在没有治疗的情况下(组1)在24天内达到约250mm2的大小(平均面积)(图1)。单独用VEGF受体抑制剂琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵(化合物I,治疗组2)治疗,或者单独通过sTie2表达干扰血管生成素/Tie受体系统(化合物II,治疗组3)延迟肿瘤生长,在31天时才达到约250mm2的大小。通过sTie2表达干扰血管生成素/Tie2系统和通过激酶抑制剂琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵干扰VEGF/VEGF受体系统的组合(化合物I+化合物II,治疗组4)延迟肿瘤生长,到38天时才达到约250mm2的大小。
这一结果清楚地证明相对于单独干预模式而言,干扰VEGF-A/VEGF受体系统和干扰血管生成素/Tie2受体系统的组合具有优越的作用。实施例2
功能性干扰血管生成素/Tie2受体系统和中和VEGF-A的组合在抑制肿瘤生长方面优于单独干预模式。
按照实施例1描述的方法在裸鼠内诱导源于A375v/sTie2细胞和A375v/pCEP细胞的肿瘤。每周两次用200μg腹膜内剂量的VEGF-A-中和单克隆抗体(mAb)4301-42-35治疗接受化合物I的动物,持续4周(Schlaeppi等,J.Cancer Res.Clin.Oncol.125,336-342,1999)。各种治疗方式如表2所述。当组1的肿瘤超过约1000mm3的体积时,出于伦理原因而处死动物。通过卡尺测量最大直径及其垂线来确定肿瘤生长。
表2
治疗方式 | ||
治疗组 | mAb 4301-42-35(化合物I) | sTie2(化合物II) |
组1:A375v/pCEP | - | - |
组2:A375v/pCEP | + | - |
组3:A375v/sTie2 | - | + |
组4:A375v/sTie2 | + | + |
源于A375v/pCEP对照细胞的肿瘤在没有治疗的情况下(组1)在28天内达到约1000mm3的大小(图2)。用VEGF-A-中和mAb 4301-42-35(化合物I,治疗组2)治疗的肿瘤在28天内长到约450mm3的体积。通过sTie2表达干扰血管生成素/Tie2受体系统(化合物II,治疗组3)减慢肿瘤生长,在28天内长到约600mm3的体积。通过sTie2表达干扰血管生成素/Tie系统和通过mAb 4301-42-35中和VEGF-A的组合(化合物I+化合物II,治疗组4)抑制肿瘤生长,在28天内才达到约250mm3的体积。
这清楚地证明相对于单独干预方式而言,中和VEGF-A和功能性干扰血管生成素/Tie2受体系统的组合具有优越的作用。
实施例3
功能性干扰血管生成素/Tie2受体系统和通过VEGF/VEGF受体系统靶向凝固作用诱导蛋白的组合在抑制肿瘤生长方面优于单独干预方式。
按照实施例1描述的方法在裸鼠内诱导源于A375v/sTie2细胞和A375v/pCEP细胞的肿瘤。使特异性识别人VEGF-A/VEGF受体I复合物的单链抗体(scFv)(WO 99/19361)在大肠杆菌内表达,并且通过Ran等(Cancer Res.58,4646-4653,1998)描述的方法缀合到凝固作用诱导重组人截短的组织因子(tTF)上。当肿瘤达到约200mm3的大小时,用20μg静脉内剂量的scFv-tTF缀合物在第0天和第4天治疗接受化合物I的动物。各种治疗方式如表3所述。当组1的肿瘤超过约1000mm3的体积时,出于伦理的原因处死动物。通过卡尺测量最大直径及其垂线来确定肿瘤生长。
表3
治疗方式 | ||
治疗组 | scFv-tTF缀合物(化合物I) | sTie2(化合物II) |
组1:A375v/pCEP | - | - |
组2:A375v/pCEP | + | - |
组3:A375v/sTie2 | - | + |
组4:A375v/sTie2 | + | + |
源于A375v/pCEP对照细胞的肿瘤在没有治疗的情况下(组1)在28天内达到约1000mm3的大小(图3)。用通过scFv-tTF缀合物而靶向于VEGF-A/VEGF受体I复合物的凝固作用诱导tTF(化合物I,治疗组2)治疗的肿瘤在28天内长到约500mm3的体积。通过sTie2表达干扰血管生成素/Tie2系统(化合物II,治疗组3)减慢肿瘤生长,在28天内达到约600mm3的体积。通过sTie2表达干扰血管生成素/Tie系统和靶向VEGF受体复合物的组合(化合物I+化合物II,治疗组4)抑制肿瘤生长,在28天内才达到约300mm3的体积。
这清楚地证明相对于单独干预方式而言,凝固作用诱导tTF靶向于VEGF-A/VEGF受体I复合物和功能性干扰血管生成素/Tie2受体系统的组合具有优越的作用。预期将细胞毒试剂靶向于VEGF/VEGF受体系统会有相似的作用。
实施例4
功能性干扰VEGF/VEGF受体系统和通过VEGF/VEGF受体系统靶向凝固作用诱导蛋白的组合在抑制肿瘤生长方面优于单独干预方式。
按照实施例1描述的方法在裸鼠内诱导源于A375v/pCEP细胞的肿瘤。用每日50mg/Kg口服剂量的VEGF受体酪氨酸激酶抑制剂琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵治疗接受化合物I的动物,直到28天(Wood等,Cancer Res.60,2178-2189,2000)。化合物II由特异性识别人VEGF-A/VEGF受体I复合物的单链抗体(scFv)(WO 99/19361)组成,使该抗体在大肠杆菌内表达,并且通过Ran等(Cancer Res.58,4646-4653,1998)描述的方法缀合到凝固作用诱导重组人截短的组织因子(tTF)上。当肿瘤长到约200mm3的大小时,用20μg静脉内剂量的scFv-tTF缀合物在第0天和第4天治疗接受化合物II的动物。各种治疗方式如表4所述。当组1的肿瘤超过约1000mm3的体积时,出于伦理的原因处死动物。通过卡尺测量最大直径及其垂线来确定肿瘤生长。
表4
治疗方式 | ||
治疗组 | 琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵(化合物I) | scFv-tTF缀合物(化合物II) |
组1:A375v/pCEP | - | - |
组2:A375v/pCEP | + | - |
组3:A375v/pCEP | - | + |
组4:A375v/pCEP | + | + |
源于A375v/pCEP对照细胞的肿瘤在没有治疗的情况下(组1)在28天内达到约1000mm3的大小(图4)。单独用VEGF受体抑制剂琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵治疗(化合物I,治疗组2)导致肿瘤体积降低到约550mm3。用通过scFv-tTF缀合物靶向于VEGF-A/VEGF受体I复合物的凝固作用诱导tTF(化合物II,治疗组3)治疗的肿瘤在28天内生长到约500mm3的体积。通过琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵抑制VEGF受体酪氨酸激酶和靶向VEGF受体复合物的组合(化合物I+化合物II,治疗组4)抑制肿瘤生长,在28天内达到约400mm3的体积。
这清楚地证明相对于单独干预方式而言,凝固作用诱导tTF靶向于VEGF-A/VEGF受体I复合物和功能性干扰VEGF/VEGF受体系统的组合具有优越的作用。预期将细胞毒试剂靶向于血管生成素/Tie2受体系统会有相似的作用。
实施例5
功能性干扰血管生成素/Tie2受体系统和内皮特异性靶向凝固作用诱导蛋白的组合在抑制肿瘤生长方面优于单独干预方式。
按照实施例1描述的方法在裸鼠内诱导源于A375v/sTie2细胞和A375v/pCEP细胞的肿瘤。按照Nilsson等描述的方法(Nat.Med.,in press)使由特异性识别纤连蛋白癌胚(oncofoetal)ED-B域的L19单链抗体和组织因子的胞外域组成的融合蛋白(L19 scFv-tTF)在大肠杆菌内表达。此外,D.Neri和F.Nilsson已经提供了L19 scFv-tTF的数据(会议“Advances in the application of monoclonal antibodies inclinical oncology(单克隆抗体在临床肿瘤学中的进展)”,Samos,Greece,31.May-2.June 2000)。当肿瘤达到约200mm3的大小时,用200μl盐水中20μg L19 scFv-tTF的单一静脉内剂量治疗接受化合物I的动物。各种治疗方式如表5所述。当组1的肿瘤超过约1000mm3的体积时,出于伦理的原因处死动物。通过卡尺测量最大直径及其垂线来确定肿瘤生长。
表5
治疗方式 | ||
治疗组 | L19 scFv-tTF(化合物I) | sTie2(化合物II) |
组1:A375v/pCEP | - | - |
组2:A375v/pCEP | + | - |
组3:A375v/sTie2 | - | + |
组4:A375v/sTie2 | + | + |
源于A375v/pCEP对照细胞的肿瘤在没有治疗的情况下(组1)在28天内达到约1000mm3的大小(图5)。用凝固作用诱导L19 scFv-tTF治疗(化合物I,治疗组2)的肿瘤在28天内生长到约450mm3的体积。通过sTie2表达干扰血管生成素/Tie2受体系统(化合物II,治疗组3)减慢肿瘤生长,在28天内达到约600mm3的体积。通过sTie2表达干扰血管生成素/Tie2系统和用L19 scFv-tTF靶向内皮的组合(化合物I+化合物II,治疗组4)抑制肿瘤生长,在28天内达到约250mm3的体积。
这清楚地证明相对于单独干预方式而言,L19 scFv-tTF靶向于内皮和功能性干扰血管生成素/Tie2受体系统的组合具有优越的作用。
实施例6
功能性干扰VEGF/VEGF受体系统和内皮特异性靶向凝固作用诱导蛋白的组合在抑制肿瘤生长方面优于单独干预方式。
按照实施例1描述的方法在裸鼠内诱导源于A375v/pCEP细胞的肿瘤。用每日50mg/Kg口服剂量的VEGF受体酪氨酸激酶抑制剂琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵治疗接受化合物I的动物,直到28天(Wood等,Cancer Res.60,2178-2189,2000)。化合物II由实施例5中描述的L19 scFv-tTF融合蛋白组成。当肿瘤达到约200mm3的大小时,用200μl盐水中20μg L19 scFv-tTF的静脉内剂量治疗接受化合物II的动物。各种治疗方式如表6所述。当组1的肿瘤超过约1000mm3的体积时,出于伦理的原因处死动物。通过卡尺测量最大直径及其垂线来确定肿瘤生长。
表6
治疗方式 | ||
治疗组 | 琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵(化合物I) | L19 scFv-tTF(化合物II) |
组1:A375v/pCEP | - | - |
组2:A375v/pCEP | + | - |
组3:A375v/pCEP | - | + |
组4:A375v/pCEP | + | + |
源于A375v/pCEP对照细胞的肿瘤在没有治疗的情况下(组1)在28天内达到约1000mm3的大小(图6)。单独用VEGF受体抑制剂琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵(化合物I,治疗组2)治疗的肿瘤的肿瘤体积降低到约550mm3。用靶向于内皮的凝固作用诱导L19 scFv-tTF治疗(化合物II,治疗组3)的肿瘤在28天内长到约450mm3的体积。通过琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵抑制VEGF受体酪氨酸激酶和靶向VEGF受体复合物的组合(化合物I+化合物II,治疗组4)抑制肿瘤生长,在28天内长到约200mm3的体积。
这清楚地证明L19 scFv-tTF靶向于内皮和功能性干扰VEGF/VEGF受体系统的组合相对于单独干预方式而言,具有优越的作用。
附图说明
图1显示通过特异性酪氨酸激酶抑制剂干扰VEGF/VEGF受体系统和通过可溶性受体域干扰血管生成素/Tie2受体系统的组合在抑制肿瘤生长方面的优越作用(表1中给出了组1-4的治疗方式)。
简写代表下述意义:
mock,con. = 治疗组1
mock+VEGF-A = 治疗组2
sTIE2-c113 = 治疗组3
sTIE2-c113+VEGF-A = 治疗组4
图2显示VEGF中和与功能性干扰血管生成素/Tie2受体系统的组合相对于单独干预方式而言,在肿瘤生长抑制方面的优越作用(表2中给出了组1-4的治疗方式)。
图3显示通过scFv-tTF缀合物使凝固作用诱导tTF靶向于VEGF/VEGF受体I复合物和功能性干扰血管生成素/Tie2受体系统的组合相对于单独干预方式而言,在肿瘤生长抑制方面的优越作用(表3中给出了组1-4的治疗方式)。
图4显示通过scFv-tTF缀合物使凝固作用诱导tTF靶向于VEGF/VEGF受体I复合物和通过VEGF受体酪氨酸激酶抑制剂琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵功能性干扰VEGF/VEGF受体系统的组合相对于单独干预方式而言,在肿瘤生长抑制方面的优越作用(表4中给出了组1-4的治疗方式)。
图5显示使凝固作用诱导L19 scFv-tTF融合蛋白靶向于内皮和功能性干扰血管生成素/Tie2受体系统的组合相对于单独干预方式而言,在肿瘤生长抑制方面的优越作用(表5中给出了组1-4的治疗方式)。
图6显示使凝固作用诱导L19 scFv-tTF融合蛋白靶向于内皮和通过VEGF受体酪氨酸激酶抑制剂琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵功能性干扰VEGF/VEGF受体系统的组合相对于单独干预方式而言,在肿瘤生长抑制方面的优越作用(表6中给出了组1-4的治疗方式)。
序列表<110>舍林股份公司<120>干扰VEGF/VEGF和血管生成素/Tie受体功能的组合和组合物以及它们的用途II<130>51867AEPM1XX00-P<140><141><160>59<210>1<211>1835<212>DNA<213>人<400>1ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttgg ataaccaagc 60agctctttaa gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240tatacaaaca gccaaaaaac cataatggtg ccacagggat ggagcaggga agggcatctc 300taacgtgtcc tctagtctat cttcgctaaa cagaacccac gttacacatg ataactagag 360agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480aagaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600attaaaaggc ttggatgtta agagaggaca ctcagcggtt cctgaaggga gacgctgaga 660tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720catttaagcg acaacaaaaa aaggcaaacc ccaaaacgca acctaaccaa agcaaaatct 780aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960gtgatcgtta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200ctccacgaac gggtacgcgc ttccatgaga aaggatattt ggcaatttta tattccacag 1260tcaggtgggt ctgcgatagc tcatttaatg ttaaacgcca tcaggggcct ctcctcccgt 1320ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380gggggctggc tgctggctcc gagggggcat ccgcagtccg tctggtcgtc tcctcctgca 1440ggctgggcag ctggccacca cttctccgac tcgacccctc caacaagcat cgcagggcac 1500tgtcctcggg ggtacagacc gtggtcccac attcgctacc actctgttcc acgtcatcca 1560ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggctctttc tgctggtgct 1620cttggacggg cgggtagttc tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800gagacgaacc acgcccgggg gtgcggaagc ggcct<210>2<211>581<212>DNA<213>人<400>2gttctagatt gttttattca gtaattagct cttaagaccc ctggggcctg tgctacccag 60acactaacaa cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240tggcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480aagaaaatct ttagcaatta gatgggagag aagggaaata gtacttgaaa tgtaggccct 540cacctcccca tgacatcctc catgagcctc ctgatgtagt g<210>3<211>516<212>DNA<213>人<400>3tagagatgtt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300tcctgcgcat tgcaggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcatcaaca 420tccaagatgc ttttccagtc aaaagaacca gcaaatactt ttctctggat ctcactcatg 480atgaagttcc agagtttgtt gtgtaaagtc cgtctg<210>4<211>1099<212>DNA<213>人<400>4cccacaacac aggggccctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaaggtg ccctgggtcg 180ggggtgcgtc ttggccttgc cgtgccctca tcccccggct gaggcagcga cacagcaggt 240gcaccaactc cagcaggtta agcaccaggg agatgagtcc aaccaccaac atgaagatga 300tgaagatggt cttctccgtg gggcgagaga caaagcagtc cacgaggtag gggcagggtg 360ctcgctggca cacaaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420ggaagcctgc ctctagcaca ctcttgcaga gcacactggc gacataggtg cccatcagtg 480ctccgcggat gcgcaggcga ccatcttctg ccaccgagat cttggccatc tgacgctcta 540cggccgccag cgcccgctcc acctgtgggt ccttggccgg cagtgcccgc agctccccct 600ccttctgccg cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660gggtgggtgt gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840agagcaccgt cagccagatc ttacccacca cggtcgagtg ctcctggacc tggtccagca 900acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960gcacgtcagt gtgtcagcat ggcatccttc tcgttcgccc agcaacaagc ctgcagggag 1020gtctgccacg cccgttctac cgcctgcctg ccgggcggcc caggtggagg tggggacgat 1080ggccggagtg acgcccgcg<210>5<211>1015<212>DNA<213>人<400>5gaggataggg agcctggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60aaaaagtgct ttttgaaaat gttgaggttg aaatgatggg aaccaacatt ctttggattt 120agtggggagc ataatagcaa acaccccctt ggttcgcaca tgtacaggaa tgggacccag 180ttggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaagtg gggccagggc 240ccagacccaa gaggagaggg tggtccgcag acaccccggg atgtcagcat cccccgacct 300gccttctggc ggcacctccc gggtgctgtg ttgagtcagc aggcatgggg tgagagcctg 360gtatatgctg ggaacagggt gcaggggcca agcgttcctc cttcagcctt gacttgggcc 420atgcaccccc tctcccccaa acacaaacaa gcacttctcc agtatggtgc caggacaggt 480gtcccttcag tcctctggtt atgacctcaa gtcctacttg ggccctgcag cccagcctgt 540gttgtaacct ctgcgtcctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720ctgggcaggc ttctctgtag aaccccaggg gcttcggccc agaccacagc gtcttgccct 780gagcctagag cagggagtcc cgaacttctg cattcacaga ccacctccac aattgttata 840accaaaggcc tcctgttctg ttatttcact taaatcaaca tgctattttg ttttcactca 900cttctgactt tagcctcgtg ctgagccgtg tatccatgca gtcatgttca cgtgctagtt 960acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa<210>6<211>2313<212>DNA<213>人<400>6ccagagcagg cctggtggtg agcagggacg gtgcaccgga cggcgggatc gagcaaatgg 60gtctggccat ggagcacgga gggtcctacg ctcgggcggg gggcagctct cggggctgct 120ggtattacct gcgctacttc ttcctcttcg tctccctcat ccaattcctc atcatcctgg 180ggctcgtgct cttcatggtc tatggcaacg tgcacgtgag cacagagtcc aacctgcagg 240ccaccgagcg ccgagccgag ggcctataca gtcagctcct agggctcacg gcctcccagt 300ccaacttgac caaggagctc aacttcacca cccgcgccaa ggatgccatc atgcagatgt 360ggctgaatgc tcgccgcgac ctggaccgca tcaatgccag cttccgccag tgccagggtg 420accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcatgctga 540atcagaaggt gaagacgctg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600ataaggaaag cgtgctgctg aacaaacgcg tggcggagga acagctggtt gaatgcgtga 660aaacccggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaaggtgca 720agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900ggtggaggag ctggcccgga gcctccgggc ggatatcgaa cgcgtggccc gcgagaactc 960agacctccaa cgccagaagc tggaagccca gcagggcctg cgggccagtc aggaggcgaa 1020acagaaggtg gagaaggagg ctcaggcccg ggaggccaag ctccaagctg aatgctcccg 1080gcagacccag ctagcgctgg aggagaaggc ggtgctgcgg aaggaacgag acaacctggc 1140caaggagctg gaagagaaga agagggaggc ggagcagctc aggatggagc tggccatcag 1200aaactcagcc ctggacacct gcatcaagac caagtcgcag ccgatgatgc cagtgtcaag 1260gcccatgggc cctgtcccca acccccagcc catcgaccca gctagcctgg aggagttcaa 1320gaggaagatc ctggagtccc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380ctgaggaggc tccaggcctg aggaccaagg gatggcccga ctcggcggtt tgcggaggat 1440gcagggatat gctcacagcg cccgacacaa ccccctcccg ccgcccccaa ccacccaggg 1500ccaccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcacccgcg 1560cctcacgatc cctcacccag agcacacggc cgcggagatg acgtcacgca agcaacggcg 1620ctgacgtcac atatcaccgt ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680tatagcgatg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1740acgtcacacc gagatgcagc aacgacgtca cgggccatgt cgacgtcaca catattaatg 1800tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagtg 1860acaacacaca ccatgacaac gacacctata gatatggcac caacatcaca tgcacgcatg 1920ccctttcaca cacactttct acccaattct cacctagtgt cacgttcccc cgaccctggc 1980acacgggcca aggtacccac aggatcccat cccctcccgc acagccctgg gccccagcac 2040ctcccctcct ccagcttcct ggcctcccag ccacttcctc acccccagtg cctggacccg 2100gaggtgagaa caggaagcca ttcacctccg ctccttgagc gtgagtgttt ccaggacccc 2160ctcggggccc tgagccgggg gtgagggtca cctgttgtcg ggaggggagc cactccttct 2220cccccaactc ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt 2280agtaaatcct taaaaaaaaa aaaaaaaaaa aaa<210>7<211>389<212>DNA<213>人<400>7gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttgttc 360tccttttgtg gtgtccagtg ggtaacatc<210>8<211>157<212>DNA<213>人<400>8tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60gaagcaggaa gcaagcccac tcaaacgtga aatttggcat gagggatcca gtaactttct 120cctcaatctg tgaactatat gtgagtttga tattttg<210>9<211>561<212>DNA<213>人<400>9aatagtcaaa acataaacaa aagctaatta actggcactg ttgtcacctg agactaagtg 60gatgttgttg gctgacatac aggctcagcc agcagagaaa gaattctgaa ttccccttgc 120tgaactgaac tattctgtta catatggttg acaaatctgt gtgttatttc ttttctacct 180accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgatc 480ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540ctgccccaat ttctaggaaa a<210>10<211>1508<212>DNA<213>人<400>10cacaaacacg agagactcca cggtctgcct gagcaccgcc agcctcctag gctccagcac 60tcgcaggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaatct 240gagctcaagc caggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300aggtgtgagg actgtggcaa gtgcaaatgt aaggagtgca cctacccaag gcctctgcca 360tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaacgtgat tgactatggg 420acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480tgtgctgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540ggtgtcatgt ccctcttttt gccttgttta tggtgttacc ttccagccaa gggttgcctt 600aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660aacacagttt gctgcaaagt tcccactgtc ccccctagga actttgaaaa accaacatag 720catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780atgcaaccaa ctaaacagtt ataatcttgg cactgttaat agaaagttgg gatagtcttt 840gctgtttgcg gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900ctcagctaat ggagctcaaa gtatgagata cagaacttgg tgacccatgt attgcataag 960ctaaagcaac acagacactc ctaggcaaag tttttgtttg tgaatagtac ttgcaaaact 1020tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatattttt 1080gtatatacaa taatatttgc aactgtgaaa aacaagtggt gccatactac atggcacaga 1140cacaaaatat tatactaata tgttgtacat tcggaagaat gtgaatcaat cagtatgttt 1200ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260ttcatgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320attgtttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaatattta 1380ttttaagagg catcttacaa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500aaaaaaaa<210>11<211>389<212>DNA<213>人<400>11gggcaggtga tcagggcaca catttcccgt ccattgagac agtagcattc ccggcaccca 60tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtgagaca agtgcccgac 120aggatgggtg gcccagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360acctcggccg cgaccacgct gggtaccga<210>12<211>981<212>DNA<213>人<400>12tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggctgagg atcacttgag 120cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240taggataaca acatattaat cagggcaaaa tacaaatgtg tgatgcttgt tagtagagta 300acctcagaat caaaatggaa cggttttaca gtgatatcat tatatttcat ttggcagaat 360cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420taggataaca ggtctgcctg tttgaagatg aaaaataata cccatttaaa atttgcccta 480ctcaatttcc ttctcagtca cattttaact tttaaacagc taatcactcc catctacaga 540ttaaggtgta tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagtttaaa 600ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720taccaggagc agaaccatta agctggtcca ggcaagttgg actccaccat ttcaacttcc 780agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900cactgcatct gcacccagca ccatacctca caggagtcga ctcccacgag ccgcctgtat 960ataagagttc ttttgatgac g<210>13<211>401<212>DNA<213>人<400>13ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120tctctccccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240gtggtcatca cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360acttcagcat atttagttgt cattaaaatt aagctgatat t<210>14<211>1002<212>DNA<213>人<400>14gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60acagttgtgg agaacaggtt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120tttgaaaatg ttaaatacaa gtcctattct ctttgtccag ctgggtttag ctagaggtag 180ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240gaagtaaata tctggggccc atcgcacccc cactaagtac tttgtcacca tgttgtatct 300taaaagtcat ttttcactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480tactgaaaac aatggtgcca tatgctccaa agacatttcc ccaagataac tgccaaagag 540tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600attaatacag ctcaaatgga gtagtaacca agcttttctg cccaggaagt aacaaacatc 660actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacattc 720attcaataaa cattagccaa gctaatgtcc caagccactg tgccaggtat taacaatata 780acaacaataa aagacacagt ccttcctctc aaggtgttca gtctagtagg gaagatgatt 840attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900gcctatgttc tcagatattc tggttaggtc aggagtggga acccaaaatc aattctttta 960acaaacacta aaggtgattc taacacaggc ggtgtgagga cc<210>15<211>280<212>DNA<213>人<400>15cgaggtgggc cacccgtgtc tggtctgaga tttttaaatg aggattacat tatcctattt 60ataatattcc tattctaatc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180aactgtatta tgactctcaa tatttaaaca tttaaaaaaa tgttagtgtt tgttaagcac 240caatcttaac tatttcacct gcccgggcgg ccgctcgagg<210>16<211>2041<212>DNA<213>人<400>16ccccccgcag aactcccccc tggaatagga tttttaaaac ccttgacaat tagaaatcct 60atagaggtta gcatttttta ggtaaaaata tggttgcccc tacagggatc atgcaacttc 120cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240aattttgtta ttgccttctt tagagacttt ataatctcta gttgattttc aaggacttga 300atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480caggtacata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540gaattttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaatgaa aaataaaaga 660tagatatttg ttatagtctg acattttaac agtcatagta ttagacgttt cgtgaccagt 720gcattttgga ctctctcagg atcaaaatac gagtctgcca actgtattaa atcctcctcc 780accccctcca ccagttggtc cacagcttcc tggtgggtcg ttgtcatcaa atccattggg 840ccgaaatgaa catgaagcag atgcagcttg gagggcccgg gctcgagcat tcaactcttg 900ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960tgggtctcca tttatccaga gtccactggt tgggttatta ccacttaaac cattagtact 1020atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaaataaaa acccattctt 1140ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200gtaaatgact ctgggaggat gctaatgcca gagcctcaga ctggtggtac atctgatatg 1260aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380catcagtccc tgaaggcttt aattttttag caaggttctc actaagatca gtgaagtcaa 1440catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500ccaaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atacttctga 1560tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620gttttctcag cattttgcag agaggcacag ttttcacaat aatattggtt atcaccagta 1680agaatctctg gagcccaaaa aataatttag taagtcagtt actgaaggtg tggtttcacc 1740tcccggtttc tgaggtacat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800agtgttttca gaacagtaaa actcattagg aggactgcct atggtttttt cattcacaag 1860tgagtcacag atgaaggcag ctgttgttgg attataaact actggctctt ctgaaggacc 1920gggtacagac gcttgcatta gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980gacagacatg ttttccaaag aagaggaagc acaaaacgca agcgaaagat ctgtaaaggc 2040t<210>17<211>235<212>DNA<213>人<400>17cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagacccctc 60acctctacaa ataaaaaatt aaaaaattag ccaggtgtgg cagcgaacaa ctgtagtctc 120agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aaggttacag 180tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta<210>18<211>2732<212>DNA<213>人<400>18gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120aaatattatc ttcttggtga tcacattgtg caaaatggtg aagcattcaa acactttgaa 180accagattct agcaggttgg aaaacattaa gtcttgggtg cttggcgctt tcgctcttct 240gtgtcttctt ggcctcacct ggtcctttgg gttgcttttt attaatgagg agactattgt 300gatggcatat ctcttcacta tatttaatgc tttccaggga gtgttcattt tcatctttca 360ctgtgctctc caaaagaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420ctgtggaggc ctcccaactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480cagtgctcgc tattcctctg gcacacagag tcgtataaga agaatgtgga atgatactgt 540gagaaaacaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600tcaaggtggc ataaatctta atatattatt acaggactga catcacatgg tctgagagcc 660catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagtg 720ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgctg cacaagggtg 780actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgcttttg 840agaaaatgat catttcagaa ttagtgcaca acaacttacg gggcagcagc aagactcaca 900acctcgagct cacgctacca gtcaaacctg tgattggagg tagcagcagt gaagatgatg 960ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggctg gagctccatc 1020acaaagaact cgaggcacca cttattcctc agcggactca ctcccttctg taccaacccc 1080agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140aagatcacct acagtccccc aacagagact ctctttatac aagcatgccc aatcttagag 1200actctcccta tccggagagc agccctgaca tggaagaaga cctctctccc tccaggagga 1260gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320agatgtgcta ccagatcagc aggggcaata gtgatggtta tataatcccc attaacaaag 1380aagggtgtat tccagaagga gatgttagag aaggacaaat gcagctggtt acaagtcttt 1440aatcatacag ctaaggaatt ccaagggcca catgcgagta ttaataaata aagacaccat 1500tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560tggtgtaaaa aagatgactg aaccttgcag ttctgtgaat ttttataaaa catacaaaaa 1620ctttgtatat acacagagta tactaaagtg aattatttgt tacaaagaaa agagatgcca 1680gccaggtatt ttaagattct gctgctgttt agagaaattg tgaaacaagc aaaacaaaac 1740tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800tttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatcctg tgggacaaat 1860ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920tttgcagttc actgcaaatc ttttacatta aggcaaagat tgaaaacatg cttaaccact 1980agcaatcaag ccacaggcct tatttcatat gtttcctcaa ctgtacaatg aactattctc 2040atgaaaaatg gctaaagaaa ttatattttg ttctattgct agggtaaaat aaatacattt 2100gtgtccaact gaaatataat tgtcattaaa ataattttaa agagtgaaga aaatattgtg 2160aaaagctctt ggttgcacat gttatgaaat gttttttctt acactttgtc atggtaagtt 2220ctactcattt tcacttcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280tattacttac atttaaattt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340tctttgaagc cagttatgtc atgccttgca caaaagtgat gaaatctaga aaagattgtg 2400tgtcacccct gtttattctt gaacagaggg caaagagggc actgggcact tctcacaaac 2460tttctagtga acaaaaggtg cctattcttt tttaaaaaaa taaaataaaa cataaatatt 2520actcttccat attccttctg cctatattta gtaattaatt tattttatga taaagttcta 2580atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640ttaataatga gcccatcact aatatccagt gtaaagttta acacggtttg acagtaaata 2700aatgtgaatt ttttcaagtt aaaaaaaaaa aa<210>19<211>276<212>DNA<213>人<400>19ctccctaaat gattttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120tattccctat atagcaaacc aaaaccagga cctcccaact gcatgcctca agtccctgtg 180gagcactctg gcaactggat ggccctactt gctttctgac aaaatagctg gaaaggagga 240gggaccaatt aaatacctcg gccgcgacca cgctgg<210>20<211>2361<212>DNA<213>人<400>20attgtaccag ccttgatgaa cgtgggccct gcttcgcttt tgagggccat aagctcattg 60cccactggtt tagaggctac cttatcattg tctcccgtga ccggaaggtt tctcccaagt 120cagagtttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgtagtggat gtgcttgctg 240agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360ttgccaagag ccagcatctg gacagtgatg ggctggccca gattttcatg cagtatggag 420accatctcta cagcaagggc aaccacgatg gggctgtcca gcaatatatc cgaaccattg 480gaaagttgga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccaccc 600tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcatcaaga 660aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaaggtc ctccggcagg 720ctggctacta ctcccatgcc ctgtatctgg cggagaacca tgcacatcat gagtggtacc 780tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggcaagc 840tgccttttga gcaggcagag agcaacatga agcgctacgg caagatcctc atgcaccaca 900taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960aaggccgcag cgatagggag gccccaggct gcagggccaa ctctgaggag ttcatcccca 1020tctttgccaa taacccgcga gagctgaaag ccttcctaga gcacatgagt gaagtgcagc 1080cagactcacc ccaggggatc tacgacacac tccttgagct gcgactgcag aactgggccc 1140acgagaagga tccacaggtc aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200gtggtcgctt ctgcgacgtc tttgacaagg ccctggtcct gtgccagatg cacgacttcc 1260aggatggtgt cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320acatgcagca cgagcagtac cggcaggtca tcagcgtgtg tgagcgccat ggggagcagg 1380acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcca cctcttctag 1500tggtgcagac cctggcccac aactccacag ccacactctc cgtcatcagg gactacctgg 1560tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgcgg gtgcggcggt 1620accgagagga gaccacccgt atccgccagg agatccaaga gctcaaggcc agtcctaaga 1680ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740tcctgtgtgg ccactccttc caccaacact gctttgagag ttactcggaa agtgatgctg 1800actgccccac ctgcctccct gaaaaccgga aggtcatgga tatgatccgg gcccaggaac 1860agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920ctgtgattgc tgactacttt ggcagaggtg ttttcaacaa attgactctg ctgaccgacc 1980ctcccacagc cagactgacc tccagcctgg aggctgggct gcaacgcgac ctactcatgc 2040actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100agaacagaca caatgggacc tgggcgggcg ttacacagaa ggctggctga catgcccagg 2160gctccactct catctaatgt cacagccctc acaagactaa agcggaactt tttcttttcc 2220ctggccttcc ttaattttaa gtcaagcttg gcaatccctt cctctttaac taggcaggtg 2280ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340ttggaaaaaa aagctggttt c<210>21<211>179<212>DNA<213>人<400>21aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc<210>22<211>905<212>DNA<213>人<400>22tttttttttt ttctttaacc gtgtggtctt tatttcagtg ccagtgttac agatacaaca 60caaatgttcc agttagaagg aattcaaacg gaatgccaag gtccaagcca ggctcaagaa 120ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttcctaaggg 180caaaggtact tttgatacag agtctgatct ttgaaactgg tgaactcctc ttccacccat 240taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtggtgggaa 300tagggtcatt aataactatg aatatatctt ttagaaggtg accattttgc actttaaagg 360gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420gggagctgga agagccttgg aagtttctat tacaaataga gcaccatatc cttcatgcca 480aatctcaaca aaagctcttt ttaactccat ctgtccagtg tttacaaata aactcgcaag 540gtctgaccag ttcttggtaa caaacataca tgtgtgtgtc tgtgtgtata cagcaatgca 600cagaaaaggc taccaggagc ctaatgcctc tttcaaacat tgggggaacc agtagaaaaa 660ggcagggctc cctaatgtcc attattacat ttccattccg aatgccagat gttaaaagtg 720cctgaagatg gtaacccagc tagtgaggaa taaatacccc accttgccca gtccacagag 780aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagtgag tgttttttcg 840ccatggattg cagtcctctc ctccagacca gctgcttatt tcctcagggg cccagggaat 900gttga<210>23<211>2134<212>DNA<213>人<400>23ggtctcttct ttcctttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60gtataaatac tctattttat atgcacttcc acaaaagcga tataatttaa aagttttttt 120cattagaaat aaatgtataa aaataaatat gttattatag gcatttatta ctaactatag 180tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300accaggatac gactgttgga ccagctgctg gagatggacc tgctacccct cagcagcctc 360cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420tcatttttgt tccggcgttt catcctcctt gtgtgattgt actgattttc atgagacaca 480agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaagt 540tggaggtact aagctcattg tgtctcctct agcttttacc agcatctaat gcttcactgc 600tttttttcca ttgtagactt taatgcactt gaataaatac atggagttgt tttttcctca 660aaatgaatta cacaaataaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720gttatttcac gttgctgagc ctttctctca tgttgaacaa tctgaagttt taattctcgg 780tagaaataat gtataaacat tctctgaaac catagcagcc ataaacagtg ctggtcaaag 840atcctatttg tactcctttc tccccccatt gttagtgagg taaagtaaaa caggtcttag 900taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtatttgat 960aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttgttttt 1020tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggctttatta 1080tgctatatca ctgctcagag gttaataatc ctcactaact atcctatcaa atttgcaact 1140ggcagtttac tctgatgatt caactccttt tctatctacc cccataatcc caccttactg 1200atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260gcaccagccc ttcctcactt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440ccttcccaca ggtcttagaa catgatgacc actcccccag ctgccactgg gggcagggat 1500ggtctgcaca aggtctggtg ctggctggct tcacttcctt tgcacactcg gaagcaggct 1560gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaagggca ttgcccacag 1740taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800ccgcagagga gccgctgtac ctcaagacaa cacctttgta cataatgtct tgctctaagg 1860tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920agctgccatt gttcctggat cccctctggt tccgctgttt cacttcgatg ttggtggctc 1980cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040tttttttaca agtagatcca tttcccccgc aaacaccaca tttatcaaac ttctttttgg 2100agtctatgat gcgatcacaa ccagctttta caca<210>24<211>1626<212>DNA<213>人<400>24ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatattttgg 60ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gttaaggctg 180tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300gaaaaaggca agacaaatgg cctcttgtac tgaatacttc ggcaaactta ttgggtcttc 360attttctgac agacaggatt tgactcaata tttgtagagc ttgcgtagaa tggattacat 420ggtagtgatg cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggttttag 540aaagctttgt ctaaaaattt ggcctaggaa tggtaacttc attttcagtt gccaaggggt 600agaaaaataa tatgtgtgtt gttatgttta tgttaacata ttattaggta ctatctatga 660atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgctggcag 780ccatctcttt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840tctggaatgc attagttatg ccttgtacca ttcccagaat ttcaggggca tcgtgggttt 900ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140aactaagata tttatctatg aagatataaa tggtgcagag agactttcat ctgtggattg 1200cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260atggattctt ctatagctaa atgagttccc tctggggaga gttctggtac tgcaatcaca 1320atgccagatg gtgtttatgg gctatttgtg taagtaagtg gtaagatgct atgaagtaag 1380tgtgtttgtt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440tggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500attatacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatattt 1560tacttgaaaa tattttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620aaaaaa<210>25<211>1420<212>DNA<213>人<400>25gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60ttcattgaaa tccttgctac ttctcttcct cctcaatgaa agacacgaga gacaagagcg 120acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180ttggaaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300tccttgtact gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360tattttataa ggcccataaa tactggttaa actctgttaa aagtgggcct tctatcttgg 420atggtttcac tgccatcagc catgctgata tattagaaat ggcatcccta tctacttact 480ttaatgctta aaattataca taaaatgctt tatttagaaa acctacatga tacagtggtg 540tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 600agggtggaga aagaggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660atcctttgca tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780tttgctctgt tttgcctgaa gttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840accagtacct ggggaggtta gatgtgtgtt tcaggcttgg agtgtatgag tggttttgct 900tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960gtggctttgt ttttttttct caagtaaaat tgtgaacata tttcctttat aggggcaggg 1020catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080tcgacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttggtt aggttactgt 1140acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa attttgtttt 1200tatagaaatt ttttatactg attggttcat agatggtcag ttttgtacac agactgaaca 1260atacagcact ttgccaaaaa tgagtgtagc attgtttaaa cattgtgtgt taacacctgt 1320tctttgtaat tgggttgtgg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380agtaaataaa gtgtccttta acttcaaaaa aaaaaaaaaa<210>26<211>689<212>DNA<213>人<400>26aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60caaacaatta tagcacatcc ttccttttac tctgtctcac ctcctttagg tgagtacttc 120cttaaataag tgctaaacat acatatacgg aacttgaaag ctttggttag ccttgcctta 180ggtaatcagc ctagtttaca ctgtttccag ggagtagttg aattactata aaccattagc 240cacttgtctc tgcaccattt atcacaccag gacagggtct ctcaacctgg gcgctactgt 300catttggggc caggtgattc ttccttgcaa gggctgtcct gtacctgccc gggcggccgc 360tcgaagcgtg gtcgcggccg aggtactgaa aggaccaagg agctctggct gccctcagga 420attccaaatg accgaaggaa caaagcttca gggctctggg tggtgtctcc cactattcag 480gaggtggtcg gaggtaacgc agcttcattt cgtccagtcc tttccagtat ttaaagttgt 540tgtcaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660cacacccaga gcctgaagtt tgtccttcg<210>27<211>471<212>DNA<213>人<400>27tcccagcggc atgaagtttg agattggcca ggccctgtac ctgggcttca tctccttcgt 60ccctctcgct cattggtggc accctgcttt gcctgtcctg ccaggacgag gcaccctaca 120agccctaacc caggccccgc ccagggccac cacgaccact gcaaacaccg cacctgccta 180ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcgg ccaccacagc 240gggtacaggc tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgctg 300tgggctggtt cccggcggga ctgtcaatgg aggcaggggt tccagcacaa agtttacttc 360tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a<210>28<211>929<212>DNA<213>人<400>28ggtgaactca gtgcattggg ccaatggttc gacacaggct ctgccagcca caaccatcct 60gctgcttctg acggtttggc tgctggtggg ctttcccctc actgtcattg gaggcatctt 120tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccggga 180gattccaccc cagccctggt acaagtctac tgtcatccac atgactgttg gaggcttcct 240gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360ttgcatctcc attgcactca cctacttcca gttgtctggg gaggattacc gctggtggtg 420gcgatctgtg ctgagtgttg gctccaccgg cctcttcatc ttcctctact cagttttcta 480ttatgcccgg cgctccaaca tgtctggggc agtacagaca gtagagttct tcggctactc 540cttactcact ggttatgtct tcttcctcat gctgggcacc atctcctttt tttcttccct 600aaagttcatc cggtatatct atgttaacct caagatggac tgagttctgt atggcagaac 660tattgctgtt ctctcccttt cttcatgccc tgttgaactc tcctaccagc ttctcttctg 720attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780ccagagaggg cctggaaatt ataaatctct atcacataag gattatatat ttgaactttt 840taagttgcct ttagttttgg tcctgatttt tctttttaca attaccaaaa taaaatttat 900taagaaaaag aaaaaaaaaa aaaaaaaaa<210>29<211>1775<212>DNA<213>人<400>29gaacgtgatg ggaactttgg gaggatgtct gagaaaatgt ccgaagggat tttggccaac 60accagaaaac gccaatgtcc taggaattcc ctcccaaaat gcttcccaaa aaattactca 120ttgacaattc aaattgcact tggctggcgg cagcccgggc ggccttcagt ccgtgtgggg 180cgcccgcgtg gccttctcct cgtaggactc cccaaactcg ttcactctgc gtttatccac 240aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300cagccggtga gacgtgggca tggtgatgat gaaggcaaag acgtcatcaa tgaaggtgtt 360gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca acttgtagtt 420cacaaagagc tggggcagca tgaagaggaa accaaaggca tagaccccgt tgacgaagct 480gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540cccgacacag agagggtaca gcaggtatga caagtacttc atggcctgag tatcgtactc 600ctcggttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660ccaaaaaata gtcatcttca atgccttctt cactttccac agctcaatgg cggctccaac 720acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780cacggtgctg aagcagcgcc agagcactgc cttggtggac atgccgatca tgctcttctt 840cttcttccag aaactgatgt catttttaaa ggccaggaaa tcaaagagaa gatggaacgc 900tgcgacaaag aaggtcagcg ccaggaagta taagttggta tctacaaaaa ttcctttcac 960ctcatcagca tctttctctg aaaacccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020gtggatccag aagcgcagcc gccccagtga gaccttgtcg taggacacgg tgaggggcag 1080ctcggtggtg gagcggttta tgaccatcag gtccttcacg cggttgctga gctggtcgat 1140gaacaggatg ggcaggtaat gcacggtttt ccccagctgg atcatcttca tgtaccgatg 1200cacatcggca ggcagggagg acccgtcaaa gacaaagttg tccgccatca cgttcagcgc 1260cagccgcggt cgccagtggg acactggctc atccagggca ctcgtcggct tcttctccgc 1320ctcgatctgc tgtgtatcag actccccggt gagcaggttg atttcttctg gcttggggac 1380catgtaggtg gtcagaggac tgaccaggtg cacctgcttc ccgtcgtgcc acggcaggac 1440cccagcgtga tggaggaaga tgtaggcata cagcgtccca ttgtttctcg ttttctttgg 1500tacagaaaca ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560gaccaggtcg atgttgttct cagcacccag gtgggacctc gtcgtggtgt acacgctcag 1620ctgcagcttg ggccgccgcg ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680gcgggtgtag acgatgccgt acatgaccca gcaggtgtgc accacgtaga ccacgaacac 1740gcccaccacc aagctggtga aggagctgcg gcccc<210>30<211>1546<212>DNA<213>人<400>30aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgctaat 60 aaggccctgccaggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120acaccatcta cgggcaccat ggaactgctt caagtgacca ttctttttct tctgcccagt 180atttgcagca gtaacagcac aggtgtttta gaggcagcta ataattcact tgttgttact 240acaacaaaac catctataac aacaccaaac acagaatcat tacagaaaaa tgttgtcaca 300ccaacaactg gaacaactcc taaaggaaca atcaccaatg aattacttaa aatgtctctg 360atgtcaacag ctactttttt aacaagtaaa gatgaaggat tgaaagccac aaccactgat 420gtcaggaaga atgactccat catttcaaac gtaacagtaa caagtgttac acttccaaat 480gctgtttcaa cattacaaag ttccaaaccc aagactgaaa ctcagagttc aattaaaaca 540acagaaatac caggtagtgt tctacaacca gatgcatcac cttctaaaac tggtacatta 600acctcaatac cagttacaat tccagaaaac acctcacagt ctcaagtaat aggcactgag 660ggtggaaaaa atgcaagcac ttcagcaacc agccggtctt attccagtat tattttgccg 720gtggttattg ctttgattgt aataacactt tcagtatttg ttctggtggg tttgtaccga 780atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840aaagagagcg tgaagcttct taccgttaag acaatttctc atgagtctgg tgagcactct 900gcacaaggaa aaaccaagaa ctgacagctt gaggaattct ctccacacct aggcaataat 960tacgcttaat cttcagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020aatcccgact tccatacctg ctgctggact gtaccagacg tctgtcccag taaagtgatg 1080tccagctgac atgcaataat ttgatggaat caaaaagaac cccggggctc tcctgttctc 1140tcacatttaa aaattccatt actccattta caggagcgtt cctaggaaaa ggaattttag 1200gaggagaatt tgtgagcagt gaatctgaca gcccaggagg tgggctcgct gataggcatg 1260actttcctta atgtttaaag ttttccgggc caagaatttt tatccatgaa gactttccta 1320cttttctcgg tgttcttata ttacctactg ttagtattta ttgtttacca ctatgttaat 1380gcagggaaaa gttgcacgtg tattattaaa tattaggtag aaatcatacc atgctacttt 1440gtacatataa gtattttatt cctgctttcg tgttactttt aataaataac tactgtactc 1500aatactctaa aaatactata acatgactgt gaaaatggca aaaaaa<210>31<211>750<212>DNA<213>人<400>31cacttgggca cccccatttt ctaaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60aagggaagtg cctctgatgg cccaaaaacc ttcttccaaa ctagtgtagg aatggaatgg 120atagcaaatg gatccttttt ggcctccttt ggagcatgcc ttccctatct tatccttggc 180cccactaaag cagaacgtta cggatatttc tgtttttgcc attggatgcc tatctggcca 240aacagccttt ccctaattgg aaaatgcagt cctgtttaaa acctttgatt tacgactact 300tgtacatgct tgctcattac aattttgaca ttttttacat agtgaagacc ccaaacatat 360cagtgaaaca tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttaca 420gtggcaagcc aattttgaaa tatctcattt aaaactcaga cccaattcac tgagttatac 480ttttaatagc ttcctcagca cactatttcc catgcattaa atatgataaa ataatctatc 540actgcccatc ggtcttgtaa aaaggaagtc tgaatacaga gcccacaaca ctaaaattgt 600ttttctagct acaaagtata gcatcatcaa cacagacacg atttggactc cctgacaggt 660ggattggaaa acggtgttta aagagaagag aacattttaa cataaatgtc attaagaatc 720ccaaaggcct tatttgtcac caccgtcccg<210>32<211>1620<212>DNA<213>人<400>32gcaattcccc cctcccacta aacgactccc agtaattatg tttacaaccc attggatgca 60gtgcagccat tcataagaac cttggtgccc cagaaaaatc tgtccttttt ggtaccaaac 120ctgaggtctt ttggaagata atgtagaaaa ccactaccta ttgaaggcct gttttggcta 180atctgtgcaa actctgatga tacctgcctt atgtggattc ttttccacac tgctttcatt 240tttaagtata aagacttaga aaactagaat aatgctttta caaataatta aaagtatgtg 300atgttctggg ttttttcctt ctttttagaa ccccgcctcc atttaaaaaa ttaaaaaaaa 360aaaaaaaact tttaacattt aaaaaataaa aattaacaaa atttcactta ttccaggaca 420cgctggcatt tggactcaat gaaaagggca cctaaagaaa ataaggctga ctgaatgttt 480tccataattt tcacacaata acagtccctt tctatccagc ttgccttcca tttatctcta 540gggttagctt ttcaggcaac atccttggtc attgcccaga aagtacctga gctatcagtg 600attggaatgg cacaggaaac cgaatcacat gggtgccctc cccttggttt tcaagtatct 660tggagttgtg cacaaaaatt aggtcatgcc ttcagtgtct tgttctttaa acctaccctt 720tgacaatcag gtgctaatga ttgtatacta ttaaaaccag cacataagta ttgtaaatgt 780gtgttcctcc taggttggaa gaaatgtctt tccttctatc tgggtcctgt taaagcgggt 840gtcagttgtg tcttttcacc tcgatttgtg aattaataga attgggggga gaggaaatga 900tgatgtcaat taagtttcag gtttggcatg atcatcattc tcgatgatat tctcactttg 960tcgcaaatct gcccttatcg taagaacaag tttcagaatt ttccctccac tatacgactc 1020cagtattatg tttacaatcc attggatgag tgcagcatta taagaccttg gtgcccagaa 1080aaatctgtcc tttttggtac caaacctgag gtcttttgga agataatgta gaaaaccact 1140acctattgaa ggcctgtttt ggctaatctg tgcaaactct gatgatacct gcttatgtgg 1200attcttttcc acactgcttt catttttaag tataaagact tagaaaacta gaataatgct 1260tttacaaata attaaaagta tgtgatgttc tgggtttttt ccttcttttt agaaccctgt 1320atttaaacaa gccttctttt taagtcttgt ttgaaattta agtctcagat cttctggata 1380ccaaatcaaa aacccaacgc gtaaaacagg gcagtatttg tgttcctaat tttaaaaagc 1440tttatgtata ctctataaat atagatgcat aaacaacact tccccttgag tagcacatca 1500acatacagca ttgtacatta caatgaaaat gtgtaactta agggtattat atatataaat 1560acatatatac ctttgtaacc tttatactgt aaataaaaaa gttgctttag tcaaaaaaaa 1620<210>33<211>2968<212>DNA<213>人<400>33gaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaaccctga agaggaggag 60gaggaggaag aagaggaaga agaagatgaa gaaagtgaag aggaggagga agaggaggga 120gaaagtgaag gcagtgaagg tgatgaggaa gatgaaaagg tgtcagatga gaaggattca 180gggaagacat tagataaaaa gccaagtaaa gaaatgagct cagattctga atatgactct 240gatgatgatc ggactaaaga agaaagggct tatgacaaag caaaacggag gattgagaaa 300cggcgacttg aacatagtaa aaatgtaaac accgaaaagc taagagcccc tattatctgc 360gtacttgggc atgtggacac agggaagaca aaaattctag ataagctccg tcacacacat 420gtacaagatg gtgaagcagg tggtatcaca caacaaattg gggccaccaa tgttcctctt 480gaagctatta atgaacagac taagatgatt aaaaattttg atagagagaa tgtacggatt 540ccaggaatgc taattattga tactcctggg catgaatctt tcagtaatct gagaaataga 600ggaagctctc tttgtgacat tgccatttta gttgttgata ttatgcatgg tttggagccc 660cagacaattg agtctatcaa ccttctcaaa tctaaaaaat gtcccttcat tgttgcactc 720aataagattg ataggttata tgattggaaa aagagtcctg actctgatgt ggctgctact 780ttaaagaagc agaaaaagaa tacaaaagat gaatttgagg agcgagcaaa ggctattatt 840gtagaatttg cacagcaggg tttgaatgct gctttgtttt atgagaataa agatccccgc 900acttttgtgt ctttggtacc tacctctgca catactggtg atggcatggg aagtctgatc 960taccttcttg tagagttaac tcagaccatg ttgagcaaga gacttgcaca ctgtgaagag 1020ctgagagcac aggtgatgga ggttaaagct ctcccgggga tgggcaccac tatagatgtc 1080atcttgatca atgggcgttt gaaggaagga gatacaatca ttgttcctgg agtagaaggg 1140cccattgtaa ctcagattcg aggcctcctg ttacctcctc ctatgaagga attacgagtg 1200aagaaccagt atgaaaagca taaagaagta gaagcagctc agggggtaaa gattcttgga 1260aaagacctgg agaaaacatt ggctggttta cccctccttg tggcttataa agaagatgaa 1320atccctgttc ttaaagatga attgatccat gagttaaagc agacactaaa tgctatcaaa 1380ttagaagaaa aaggagtcta tgtccaggca tctacactgg gttctttgga agctctactg 1440gaatttctga aaacatcaga agtgccctat gcaggaatta acattggccc agtgcataaa 1500aaagatgtta tgaaggcttc agtgatgttg gaacatgacc ctcagtatgc agtaattttg 1560gccttcgatg tgagaattga acgagatgca caagaaatgg ctgatagttt aggagttaga 1620atttttagtg cagaaattat ttatcattta tttgatgcct ttacaaaata tagacaagac 1680tacaagaaac agaaacaaga agaatttaag cacatagcag tatttccctg caagataaaa 1740atcctccctc agtacatttt taattctcga gatccgatag tgatgggggt gacggtggaa 1800gcaggtcagg tgaaacaggg gacacccatg tgtgtcccaa gcaaaaattt tgttgacatc 1860ggaatagtaa caagtattga aataaaccat aaacaagtgg atgttgcaaa aaaaggacaa 1920gaagtttgtg taaaaataga acctatccct ggtgagtcac ccaaaatgtt tggaagacat 1980tttgaagcta cagatattct tgttagtaag atcagccggc agtccattga tgcactcaaa 2040gactggttca gagatgaaat gcagaagagt gactggcagc ttattgtgga gctgaagaaa 2100gtatttgaaa tcatctaatt ttttcacatg gagcaggaac tggagtaaat gcaatactgt 2160gttgtaatat cccaacaaaa atcagacaaa aaatggaaca gacgtatttg gacactgatg 2220gacttaagta tggaaggaag aaaaataggt gtataaaatg ttttccatga gaaaccaaga 2280aacttacact ggtttgacag tggtcagtta catgtcccca cagttccaat gtgcctgttc 2340actcacctct cccttcccca acccttctct acttggctgc tgttttaaag tttgcccttc 2400cccaaatttg gatttttatt acagatctaa agctctttcg attttatact gattaaatca 2460gtactgcagt atttgattaa aaaaaaaaaa gcagattttg tgattcttgg gacttttttg 2520acgtaagaaa tacttcttta tttatgcata ttcttcccac agtgattttt ccagcattct 2580tctgccatat gcctttaggg cttttataaa atagaaaatt aggcattctg atatttcttt 2640agctgctttg tgtgaaacca tggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760catccaccag taagcaagct ctgttaggct tccatggtta gtggtagctt ctctcccaca 2820agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940tgatcggttt agtagagatt ttatacat<210>34<211>6011<212>DNA<213>人<400>34acggggcgcc ggacgacccg cacatcttat cctccacgcc ccactcgcac tcggagcggg 60accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgccggcc 120cggcttgagc cgagcgcagc accccccgcg ccccgcgcca gaagtttggt tgaaccgggc 180tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240ggaactcccc cggcccaagg ctcgtgggct cggggtcgcg cggccgcaga aggggcgggg 300tccgcccgcg aggggaggcg cccccgggga cccgagaggg gggtgaggac cgcgggctgc 360tggtgcggcg gcggcagcgt gtgccccgcg caggggaggc gccgccccgc tcccggcccg 420gctgcgagga ggaggcggcg gcggcgcagg aggatgtact tggtggcggg ggacaggggg 480ttggccggct gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccggcgcgc 540tccggcaccc gggcgctggt ctgcctgccc tgtgacgagt ccaagtgcga ggagcccagg 600aaccgcccgg ggagcatcgt gcagggcgtc tgcggctgct gctacacgtg cgccagccag 660gggaacgaga gctgcggcgg caccttcggg atttacggaa cctgcgaccg ggggctgcgt 720tgtgtcatcc gccccccgct caatggcgac tccctcaccg agtacgaagc gggcgtttgc 780gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900aatccctttg agtttccaag tcaggatatg tgcctttcag ctttaaagag aattgaagaa 960gagaagccag attgctccaa ggcccgctgt gaagtccagt tctctccacg ttgtcctgaa 1020gattctgttc tgatcgaggg ttatgctcct cctggggagt gctgtccctt acccagccgc 1080tgcgtgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140ctagtgtcaa aagcctcagg gaagccggga gagtgctgtg acctctatga gtgcaaacca 1200gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac tttgccaaca 1320agatgcgagt gtctctctgg cttatgtggt ttccccgtgt gtgaggtggg atccactccc 1380cgcatagtct ctcgtggcga tgggacacct ggaaagtgct gtgatgtctt tgaatgtgtt 1440aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500cgaatggaca actgtcggtt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560cagtgtggtg agataaactg cgagaggtac tacgtgcccg aaggagagtg ctgcccagtg 1620tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgccaa tggcctgatc 1680cttgcccacg gagaccggtg gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaaccctgt gaaagtgcct 1800ggggagtgtt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920cacaatggtt gtcggacctg tcagtgcata aacacccagg aactatgttc agaacgtaaa 1980caaggctgca ccttgaactg tcccttcggt ttccttactg atgcccaaaa ctgtgagatc 2040tgtgagtgcc gcccaaggcc caagaagtgc agacccataa tctgtgacaa gtattgtcca 2100cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttatc 2220tgcaagtgca gagaggcctc tgcttcagct gggccaccca tcctgtcggg cacttgtctc 2280accgtggatg gtcatcatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgcctgtggc 2400aaccccacca ttcaccctgg acagtgctgc ccatcatgtg cagatgactt tgtggtgcag 2460aagccagagc tcagtactcc ctccatttgc cacgcccctg gaggagaata ctttgtggaa 2520ggagaaacgt ggaacattga ctcctgtact cagtgcacct gccacagcgg acgggtgctg 2580tgtgagacag aggtgtgccc accgctgctc tgccagaacc cctcacgcac ccaggattcc 2640tgctgcccac agtgtacaga tcaacctttt cggccttcct tgtcccgcaa taacagcgta 2700cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760gacgtttgta ccagctgcat ctgcattgat agcgtaatta gctgtttctc tgagtcctgc 2820ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgttgtcc ctactgcata 2880aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940gagcggtggg accttgacag ctgcacccac tgctactgcc tgcagggcca gaccctctgc 3000tcgaccgtca gctgcccccc tctgccctgt gttgagccca tcaacgtgga aggaagttgc 3060tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120aaccatcgag gagaggttga cctggaggtt cccctgtggc ccacgcctag tgaaaatgat 3180atcgtccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240cacccaagtg aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300tgcctctcta ttataatagc attcctattc atcaatcaga agaaacagtg gataccactg 3360ctttgctggt atcgaacacc aactaagcct tcttccttaa ataatcagct agtatctgtg 3420gactgcaaga aaggaaccag agtccaggtg gacagttccc agagaatgct aagaattgca 3480gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600gacgactaaa tctgctctaa aaagtaaact agaatttgtg cacttgctta gtggattgta 3660ttggattgtg acttgatgta cagcgctaag accttactgg gatgggctct gtctacagca 3720atgtgcagaa caagcattcc cacttttcct caagataact gaccaagtgt tttcttagaa 3780ccaaagtttt taaagttgct aagatatatt tgcctgtaag atagctgtag agatatttgg 3840ggtggggaca gtgagtttgg atggggaaag gggtgggagg gtggtgttgg gaagaaaaat 3900tggtcagctt ggctcgggga gaaacctggt aacataaaag cagttcagtg gcccagaggt 3960tatttttttc ctattgctct gaagactgca ctggttgctg caaagctcag gcctgaatga 4020gcaggaaaca aaaaaggcct tgcgacccag ctgccataac caccttagaa ctaccagacg 4080agcacatcag aaccctttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140cagtcacaac tgcagtaggc agtgaggaag ccagagaaat gcgatagcgg catttctcta 4200aagcgggtta ttaaggatat atacagttac actttttgct gcttttattt tcttccaagc 4260caatcaatca gccagttcct agcagagtca gcacatgaac aagatctaag tcatttcttg 4320atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggaggg agagggtgac 4380gaacaccagg catttccagg ggctatattt cactgtttgt tgttgctttg ttctgttata 4440ttgttggttg ttcatagttt ttgttgaagc tctagcttaa gaagaaactt tttttaaaaa 4500gactgtttgg ggattctttt tccttattat atactgattc tacaaaatag aaactacttc 4560attttaattg tatattattc aagcaccttt gttgaagctc aaaaaaaatg atgcctcttt 4620aaactttagc aattatagga gtatttatgt aactatctta tgcttcaaaa aacaaaagta 4680tttgtgtgca tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740tgttttcctg ttgaatgtat ttttatgaga ttttaaccag aacaaaggca gataaacagg 4800cattccatag cagtgctttt gatcacttac aaattttttg aataacacaa aatctcattc 4860tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920gtgtgtgcgc gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980attcctttat taaaatcttc ctcatttgga tttgctttca gttggttttc aatttgctca 5040ctggccagag acattgatgg cagttcttat ctgcatcact aatcagctcc tggatttttt 5100tttttttttt tcaaacaatg gtttgaaaca actactggaa tattgtccac aataagctgg 5160aagtttgttg tagtatgcct caaatataac tgactgtata ctatagtggt aacttttcaa 5220acagccctta gcacttttat actaattaac ccatttgtgc attgagtttt cttttaaaaa 5280tgcttgttgt gaaagacaca gatacccagt atgcttaacg tgaaaagaaa atgtgttctg 5340ttttgtaaag gaactttcaa gtattgttgt aaatacttgg acagaggttg ctgaacttta 5400aaaaaaatta atttattatt ataatgacct aatttattaa tctgaagatt aaccattttt 5460ttgtcttaga atatcaaaaa gaaaaagaaa aaggtgttct agctgtttgc atcaaaggaa 5520aaaaagattt attatcaagg ggcaatattt ttatcttttc caaaataaat ttgttaatga 5580tacattacaa aaatagattg acatcagcct gattagtata aattttgttg gtaattaatc 5640cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5700caatcatggc catattatga aaatactaac aggatatagg acaaggtgta aattttttta 5760ttattatttt aaagatatga tttatcctga gtgctgtatc tattactctt ttactttggt 5820tcctgttgtg ctcttgtaaa agaaaaatat aatttcctga agaataaaat agatatatgg 5880cacttggagt gcatcatagt tctacagttt gtttttgttt tcttcaaaaa agctgtaaga 5940gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000aaaaaaaaaa a<210>34a<211>1036<212>DNA<213>人<400>34amylvagdrgl agcghllvsl lgllllpars gtralvclpc deskceeprn rpgsivqgvc 60gccytcasqg nescggtfgi ygtcdrglrc virpplngds lteyeagvce denwtddqll 120 gfkpcnenliagcniingkc ecntirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180 vqfsprcped svliegyappgeccplpsrc vcnpagclrk vcqpgnlnil vskasgkpge 240 ccdlyeckpv fgvdcrtvec ptvqqtacppdsyetqvrlt adgcctlptr ceclsglcgf 300 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnnveyydgdmfr mdncrfcrcq 360ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420 ctfcqcvngerhcvatvcgq tctnpvkvpg eccpvceept iitvdppacg elsnctltrk 480 dcingfkrdh ngcrtcqcintqelcserkq gctlncpfgf ltdaqnceic ecrprpkkcr 540 piicdkycpl gllknkhgcd icrckkcpelscskicplgf qqdshgclic kcreasasag 600 ppilsgtclt vdghhhknee swhdgcrecy clngremcalitcpvpacgn ptihpgqccp 660scaddfvvqk pelstpsich apggeyfveg etwnidsctq ctchsgrvlc etevcppllc 720 qnpsrtqdsccpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkpd vctscicids 780 viscfsescp svscerpvlrkgqccpycik dtipkkvvch fsgkayadee rwdldscthc 840 yclqgqtlcs tvscpplpcv epinvegsccpmcpemyvpe ptnipiektn hrgevdlevp 900 lwptpsendi vhlprdmghl qvdyrdnrlh psedssldsiasvvvpiiic lsiiiaflfi 960 nqkkqwipll cwyrtptkps slnnqlvsvd ckkgtrvqvd ssqrmlriaepdarfsgfys 1020 mqkqnhlqad nfyqtv<210>35<211>716<212>DNA<213>人<400>35gcagtacctg gagtgtcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60acccggggct cctgggccgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120agaagtccag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300ttgagggaat ctcctgattc tccttatatg acctcaaact gaccatacta aacagtgtag 360aaggtctttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420gtcagtgtgg agtagacggt ttcctccacc cagggttgac tcagggggat gatctgggtc 480ccattctggt cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540tctggttagt gtcgtaacct ctgtgtgcct cccgttaccc catctgtcca gtgagctcag 600cccccatcca cctaacaggg tggccacagg gattactgag ggttaagacc ttagaactgg 660gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa<210>36<211>395<212>DNA<213>人<400>36ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca tttactacat 120tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240gcccagtaaa accaaagtca gggtaaccaa tgtcatttta caaaatgtta aaaccctaat 300tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360agaagcaagg aaagcattct taattctacc atcct<210>37<211>134<212>DNA<213>人<400>37ccctcgagcg gccgcccggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60aacccataaa gctgcctggc tttcagcaac aggcctatca acaccatggt gagtctccat 120aagggacacc gtgt<210>38<211>644<212>DNA<213>人<400>38aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120gggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180ggaatattgg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaga 360aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420ttcgcaccgg aaaatgtagc ttcccggtta agtaccttgg ccatgtagaa gttgatgaat 480caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540tcaaaggctt ctttggaaaa actggaaaga aagcagttaa agcagtttct gtgggtctaa 600gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat<210>39<211>657<212>DNA<213>人<400>39ctttttgttt gggttttcca atgtagatgt ctcagtgaaa tgtgcagata tactttgttc 60cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360tggtcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420ttttttgttt tttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600atgtttgctt caatagaaat ttgttcccac ttgtattttc aacaaaatta tcggaac<210>40<211>1328<212>DNA<213>人<400>40acaattttaa aataactagc aattaatcac agcatatcag gaaaaagtac acagtgagtt 60ctggttagtt tttgtaggct cattatggtt agggtcgtta agatgtatat aagaacctac 120ctatcatgct gtatgtatca ctcattccat tttcatgttc catgcatact cgggcatcat 180gctaatatgt atccttttaa gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240ggtaaaaaaa attccccaaa tattttgcac tgaatgtacc aaaggtgaag ggacattaca 300atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360acttccttca cagtgccgtg tctaccacta caaggactgt gcatctaagt aataattttt 420taagattcac tatatgtgat agtatgatat gcatttattt aaaatgcatt agactctctt 480ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttcccccact 540gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660actcagaact atatttctaa gcctgcattt tcactgatgc ataattttct tagtaatatt 720aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780ttaattttat gagaaggtat tcttcatttt aattgctttt gggattactc cacatctttg 840tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900attggattga catatggttt gccagcctat gggtttacag gcattgccca aacatttctt 960tgagatctat atttataagc agccatggaa ttcctattat gggatgttgg caatcttaca 1020ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080gtgagttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200tggaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320tgaaaaaa<210>41<211>987<212>DNA<213>人<400>41aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120taacccccgg ctatcagtcc ggatggttgc cacccctcct gctgtaggat ggaagcagcc 180atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300tgtctttctc ttctccaacc aacagaaaag actgctcttc aaaggtggag ggtcttcatg 360aaacacagct gccaggagcc caggcacagg gctgggggcc tggaaaaagg agggcacaca 420ggaggaggga ggagctggta gggagatgct ggctttacct aaggtctcga aacaaggagg 480gcagaatagg cagaggcctc tccgtcccag gcccattttt gacagatggc gggacggaaa 540tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggtatccaa 780aatagtctac ggccatacca ccctgaacgt gcctaatctc gtaagctaag cagggtcagg 840cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttgg 900actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960tgaagtagcg atttggtgtg aaaaaaa<210>42<211>956<212>DNA<213>人<400>42cggacggtgg ggcggacgcg tgggtgcagg agcagggcgg ctgccgactg ccccaaccaa 60ggaaggagcc cctgagtccg cctgcgcctc catccatctg tccggccaga gccggcatcc 120ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccgggga gggggcacgg 240caggcgtgtg gcagccacac gcaggcggcc agggcggcca gggacccaaa gcaggatgac 300cacgcacctc cacgccactg cctcccccga atgcatttgg aaccaaagtc taaactgagc 360tcgcagcccc cgcgccctcc ctccgcctcc catcccgctt agcgctctgg acagatggac 420gcaggccctg tccagccccc agtgcgctcg ttccggtccc cacagactgc cccagccaac 480gagattgctg gaaaccaagt caggccaggt gggcggacaa aagggccagg tgcggcctgg 540ggggaacgga tgctccgagg actggactgt ttttttcaca catcgttgcc gcagcggtgg 600gaaggaaagg cagatgtaaa tgatgtgttg gtttacaggg tatatttttg ataccttcaa 660tgaattaatt cagatgtttt acgcaaggaa ggacttaccc agtattactg ctgctgtgct 720tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780tcgcaggacc aagggggcgg ggactgctgg ctcacgcccc gctgtgtcct ccctcccctc 840ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtggt 900ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa<210>43<211>536<212>DNA<213>人<400>43aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240tctaaataaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360attttttcca gatgaaactt gtgccacttc caattgacta atgaaataca aggagacaga 420ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaatatta tggtagctaa 480agggtggttt ccccggcacc tggacctgga caggtagggt tccgtggtta accagt<210>44<211>1630<212>DNA<213>人<400>44ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180atcccctctg gagggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300gtgatttccc ttaggcccag gacttgggcc tccagctcat ctgttccttc tgggcccatt 360catggcaggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600attaggaagt cgggggtggg tggtggtggt gggctagttg ggtttgaatt taggggccga 660tgagcttggg tacgtgagca gggtgttaag ttagggtctg cctgtatttc tggtcccctt 720ggaaatgtcc ccttcttcag tgtcagacct cagtcccagt gtccatatcg tgcccagaaa 780agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctggt 840gcccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttggtggc 900tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960gagttggctg gtagagcctt ctagaggttc agaatattag cttcaggatc agctgggggt 1020atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080tgagggacag tttgggtttg ggacttacca gggtgatgtt agatctggaa cccccaagtg 1140aggctggagg gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200aaagagtgac cttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320ctgggtccct tgtagcacag gagactgggg ctaagggccc ctcccaggga agggacacca 1380tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccagagg 1440actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgcctg gctgttctct 1500cattgtcact gccctctccc caacctctcc tctaacccac tagagattgc ctgtgtcctg 1560cctcttgcct cttgtagaat gcagctctgg ccctcaataa atgcttcctg cattcatctg 1620caaaaaaaaa<210>45<211>169<212>DNA<213>人<400>45tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60taaaactggt ttatgatctt cagtctgatt ccagtgctgc ataactagat aacgtatgaa 120ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaga cttagttga<210>46<211>769<212>DNA<213>人<400>46tgcaggtcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcggtgga 60atttgtcgct ttcacttttt ataaagtgct acataaaatg tcatatttcc aaatttaaaa 120acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240aaggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420ggccagctcc tttcctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540tattttgtaa taaaatcaaa tttcccattg aaaccttcaa aaactttgca gaatgaggtt 600ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660cctgcctttt tgtttttaaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720ggacatgttg acggagagga aaggtaggaa agggttaggg atagaagcc<210>47<211>2529<212>DNA<213>人<400>47tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60gtgaaaatta gtgactggtt aaggtgtgcc actgtacata tcatcatttt ctgactgggg 120tcaggacctg gtcctagtcc acaagggtgg caggaggagg gtggaggcta agaacacaga 180aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240ggatggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300gccttactta gctcctggca gagggtgagt ggggacctac gaggttcaaa atcaaatggc 360atttggccag cctggcttta ctaacaggtt cccagagtgc ctctgttggc tgagctctcc 420tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600ccagaggccc ctgcaacttt gcggatttcc agaaggtgat aaaaagagca ctcttgagtg 660ggtgcccagg aatgtttaaa atctatcagg cacactataa agctggtggt ttcttcctac 720caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780tgaactctgg tgttgacagg tacaaaggag aagagatggg gactgtgaag aggggagggc 840ttccctcatc ttcctcaaga tctttgtttc cataaactat gcagtcataa ttgagaaaaa 900gcaatagatg gggcttccta ccatttgttg gttattgctg gggttagcca ggagcagtgt 960ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttggggtct 1020ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080aggtgaacag tcctacctgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140ttatgaaact gaaaatcaaa tcaaggtatt gggaagaata atttcccctc gattccacag 1200gagggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260acaaatcatc aggggttgcc tgcttggcag tcacatgctt ccctggtttt agcacacata 1320caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatggtgg tcttttgcat 1440gcagttgggc tgacctgaca aagcccccag tttcctgtgg caggttctgg gagaggatgc 1500attcaagctt ctgcagccta ggggacaggg ctgcttgttc agttattact gcctcggagc 1560tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920gggggagtgg gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980ctctatctga ggagccccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040tgaaaatttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaactcagg 2100tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaag 2220gcctgaagtt atagagtgtt tacagcggtg gcgatattca ggggtcatcg ccaactggtc 2280tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340ttccaggagt caagattagc caggaagcca aacaccagga gttggggtgg cacgtcacca 2400gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520ggggtgtcc<210>48<211>1553<212>DNA<213>人<400>48tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattta cacacctgac 120aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180ctagccaggc ccgttttcca tccctaagta ccattctctc atttgggccc ttctagggtt 240ggggccctga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360ccatcaagag ggctatggga gccaagtgaa cacgggggat tgaggctaat tcacctgaac 420tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttcctcga 480gacggagtct cgctgtgttg cccaggctgg agtgcagtgg cacggtctcg gctcactgca 540agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600taggtgccaa ccactacgcc tagctaattt ttttttgtat ttttagtaga gacagggttt 660caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720aagtgctggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg gggtgctctc 900cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960acttcagtgg tgcacctgga tggtggaagc cagcctttgg ggcaggaaac cagctcagag 1020aggctaccca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaaag 1080aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140ggatgagctt cactcaacgt ggagatggtg gtggactggt ccctgaaaag cgggccttgc 1200agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260cgaggggagc aggaggcttc tctctagtcc ctttggaggc tttggctgag agaagagtga 1320gcagggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaatgcc 1380tcagatcgat gtatttctct ccctggtctc ccggagccct cttgtcaccg ctgctgccct 1440gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag<210>49<211>921<212>DNA<213>人<400>49ctgtggtccc agctactcag gaggctgagg cgggaggatt gcttgagccc aggagttgga 60tgttgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120gtctcagaaa acaaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180gcctgtcaga acacttggct actcctaccc cagatcagtg gacctgggaa tgagggttgg 240tcccgggagg cttttctcca agctgttgcc accagacccg ccatgggaac cctggccaca 300gaagcctccc ggggagtgag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360ggagggtggg gagtgtgcaa gggtgtgtgt gtgcccgggg ggtgttcatg ggcaagcatg 420tgcgtgcctg tgtgtgtgcg tgcccctccc ctgcagccgt cggtggtatc tccctccagc 480cccttcgcca ccttctgagc attgtctgtc cacgtgagac tgcccagaga cagcagagct 540ccacgtggtt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600caggtgctaa atgacccgac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660gtcccgctga cctgcccccg tggcgtctca cggtgatgcc tgctcctgac attggtgttc 720actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780ttcaaataaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840tactttgacc tcttgcctac aaccccttcc ttgggtccga ggctggtagc tttgttcact 900tcagatggtt gggggcgggt g<210>50<211>338<212>DNA<213>人<400>50atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60tcccttccag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttcgt 240cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300gtaagaaact ttctttcttg aattcttggt tctcttgg<210>51<211>1191<212>DNA<213>人<400>51ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacacat ccggggatgg 60ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tgttggctct ctgtgccact 120cctggaaaat aatgaattgg gtaaggaaca gttaataaga aaatgtgcct tgctaactgt 180gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgctcctg acaagtcggg 360aatttctcta tttctccact ggtgcaaaga gcggatttct ccctgcttct cttctgtcac 420ccccgctcct ctcccccagg aggctccttg atttatggta gctttggact tgcttccccg 480tctgactgtc cttgacttct agaatggaag aagctgagct ggtgaaggga agactccagg 540ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600aagacaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780aaaaagctga actgcaaatc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960ctaggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080cttccaatac ctctggccat cagatgactt taaaaggtac aggagtaaaa gtttaagatg 1140atgggcaaaa gtccagtgta ttcagtaaag tgctaatcac aagttggagg t<210>52<211>1200<212>DNA<213>人<400>52aacagggact ctcactctat caaccccagg ctggagtccg gtgcgcccac cctggctccc 60tgcaacctcc gcctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180cgccttctgt ccaggccggc atcatatact ttaaatcatg cccagatgac tttaatacct 240aatacaatat atcaggttgg tttaaaaata attgcttttt tattattttt gcatttttgc 300accaacctta atgctatgta aatagttgtt atactgttgc ttaacaacag tatgacaatt 360ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtggtc tttttttttt 420ttctcagtgt tttcaattcc tccttggttg aatccatgga tgcaaaaccc acagatatga 480agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540atatgtagtg aaagttatgg tacagtggaa agagtagttg aaaacataaa catttggacc 600tttcaagaaa ggtagcttgg tgaagttttt caccttcaaa ctatgtccca gtcagggctc 660tgctactaat tagctataat ctttgcacaa attacatcac ctttgagtct cagttgcctc 720acctgtaaaa tgaaagaact ggatactctc taaggtcact tccagccctg tcattctata 780actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtca aactgaaaat 840gattattaaa gtgggaaaaa gccaattgct tctcttagaa agctcaacta aatttgagaa 900gaataatctt ttcaattttt taagaattta aatattttta agggtttgac ctatttattt 960agagatgggg tctcactctg tcacccagac tggagtacag tggcacaatc atagctcact 1020gctgcctcaa attcatgggc tcaagtgatc ctcctgcctc tgcctccaga gtagctgcga 1080ctatgggcat gtgccaccac gcctggctaa catttgtatt gacctattta tttattgtga 1140tttatatctt tttttttttt tctttttttt ttttttacaa aatcagaaat acttattttg 1200<210>53<211>989<212>DNA<213>人<400>53aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtgaa catttatttt 60tatgcctttc ttcctatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120gattcaatta gtccttgggc tggtcgactg tgcaggagtc cagggagcct ctacaaatgc 180agagtgactc tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttcctcca 240ggaatgtgcc atttcagatg cacagcaccc atgcagaaaa gctggaattt tccttggaac 300cgactgtgat agaggtgctt acatgaacat tgctactgtc tttctttttt tttgagacag 360gtttcgcttg tgcccaggct gagtgcaatg cgtgatctca ctcactgcaa ttccacctcc 420aggttcaagc attctcctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480ccggctaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaac 540cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660ttctctgaag tacttgataa aatttccaaa caaaacacat gtccacttca ctgataaaaa 720atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcctttttg aaatcagtta 840ttaatattat tctttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtgc actggcgcaa 960gcccggctca ccgcaatctc tgccacccg<210>54<211>250<212>DNA<213>人<400>54catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120agtggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180aaagggcatt ctttaggaac tgcatctggt aacccacacc ttgatccaag agctagggaa 240acttcagttg<210>55<211>2270<212>DNA<213>人<400>55gcgcccccga gcagcgcccg cgccctccgc gccttctccg ccgggacctc gagcgaaaga 60ggcccgcgcg ccgcccagcc ctcgcctccc tgcccaccgg gcacaccgcg ccgccacccc 120gaccccgctg cgcacggcct gtccgctgca caccagcttg ttggcgtctt cgtcgccgcg 180ctcgccccgg gctactcctg cgcgccacaa tgagctcccg catcgccagg gcgctcgcct 240tagtcgtcac ccttctccac ttgaccaggc tggcgctctc cacctgcccc gctgcctgcc 300actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctggtccgg gacggctgcg 360gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccctgcg 420accacaccaa ggggctggaa tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaaacgggg 540aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600ttcctctgtg tccccaagaa ctatctctcc ccaacttggg ctgtcccaac cctcggctgg 660tcaaagttac cgggcagtgc tgcgaggagt gggtctgtga cgaggatagt atcaaggacc 720ccatggagga ccaggacggc ctccttggca aggagctggg attcgatgcc tccgaggtgg 780agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggctcc 840ctgtttttgg aatggagcct cgcatcctat acaacccttt acaaggccag aaatgtattg 900ttcaaacaac ttcatggtcc cagtgctcaa agacctgtgg aactggtatc tccacacgag 960ttaccaatga caaccctgag tgccgccttg tgaaagaaac ccggatttgt gaggtgcggc 1020cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080aatcccccga accagtcagg tttacttacg ctggatgttt gagtgtgaag aaataccggc 1140ccaagtactg cggttcctgc gtggacggcc gatgctgcac gccccagctg accaggactg 1200tgaagatgcg gttccgctgc gaagatgggg agacattttc caagaacgtc atgatgatcc 1260agtcctgcaa atgcaactac aactgcccgc atgccaatga agcagcgttt cccttctaca 1320ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380cctagacaaa caagggagaa gagtgtcaga atcagaatca tggagaaaat gggcgggggt 1440ggtgtgggtg atgggactca ttgtagaaag gaagccttgc tcattcttga ggagcattaa 1500ggtatttcga aactgccaag ggtgctggtg cggatggaca ctaatgcagc cacgattgga 1560gaatactttg cttcatagta ttggagcaca tgttactgct tcattttgga gcttgtggag 1620ttgatgactt tctgttttct gtttgtaaat tatttgctaa gcatattttc tctaggcttt 1680tttccttttg gggttctaca gtcgtaaaag agataataag attagttgga cagtttaaag 1740cttttattcg tcctttgaca aaagtaaatg ggagggcatt ccatcccttc ctgaaggggg 1800acactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860ggtgttttaa gactgaatgt tttatttatc aaaatgtagc ttttggggag ggaggggaaa 1920tgtaatactg gaataatttg taaatgattt taattttata ttcagtgaaa agattttatt 1980tatggaatta accatttaat aaagaaatat ttacctaata tctgagtgta tgccattcgg 2040tatttttaga ggtgctccaa agtcattagg aacaacctag ctcacgtact caattattca 2100aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160ttataccttc agtagagaaa agtctttgca tataaagtaa tgtttaaaaa acatgtattg 2220aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa<210>56<211>1636<212>DNA<213>人<400>56cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaaggga 60agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgcccccac 120cagtttgatt ggaagtccag ctgtgaaacc tggagcgtcg ccttctcccc agatggctcc 180tggtttgctt ggtctcaagg acactgcatc gtcaaactga tcccctggcc gttggaggag 240cagttcatcc ctaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360agcccgtggc cttccccacc cagcaggaag ctctgggcac gccaccaccc ccaagtgccc 420gatgtctctt gcctggttct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540agcttcacac ccagtggcag tttgattttg gtctccgcgt cacgggataa gactcttcgc 600atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660gtttactgct gttccatctc cccagactgc agcatgctgt gctctgcagc tggagagaag 720tcggtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780agcagtgttg tctcttgtga cttctccccc gactctgccc tgcttgtcac ggcttcttac 840gataccaatg tgattatgtg ggacccctac accggcgaaa ggctgaggtc actccaccac 900acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020tgggccctgg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080acattttttc cacatggtgg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140tggacagctc ctagggtcct gtcctcactg aagcacttat gccggaaagc ccttcgaagt 1200ttcctaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320cctgtcaaag ggagttgctg gaataatggg ccaaacatct ggtcttgcat tgaaatagca 1380tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560aagatggtga agggtgggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620gaccctgtgc tgcgtt<210>57<211>460<212>DNA<213>人<400>57ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120tggaatgagc taaagcagcc gcctggggtg ggaggccgag cccatttgta tgcagcaggg 180ggcaggagcc cagcaaggga gcctccattc ccaggactct ggagggagct gagaccatcc 240atgcccgcag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aacccaacca 360gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420ccgagctcga attcgtaatc atggtcatag ctgtttcctg<210>58<211>1049<212>DNA<213>人<400>58atctgatcaa gaatacctgc cctggtcact ctgcggatgt ttctgtccac ttgttcacat 60tgaggaccaa gatatccttt tttacagagg cacttgttcg gtctaacaca gacacctcca 120tgacgacatg ctggctcaca ttttgcagtt ctgcagaagt ccccctccca gcctggacta 180cagcagcact ttcccgtggg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300ggatctacaa ttttgtagag ttttccattg tgagtctggg tcatactttt actgcttgat 360aaaatgtaaa cttcacctag ttcatcttct ccaaatccca agatgtgacc ggaaaagtag 420cctctacagg acccactagt gccgacacag agtggttttt cttgccactg ctttgtcaca 480ggactttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540aatctttctg actggcagcc ccggtataca aatccaccaa ccaaaggacc attactgaat 600ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960aaaaacccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020acttcaagaa agactctggc tgttctcaa<210>59<211>747<212>DNA<213>人<400>59tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120cttaaatata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcatataaa 180gttgttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300ctcgtctgtc ccacacaaat gtttaagaag tcactgcaat gtactccccg gctctgatga 360aaagaagccc ctggcacaaa agattccagt gcccctgaag aggctccctt cctcctgtgg 420gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540ccaattcaat gccacaccta ctggttaccc tttgagggca tttctccaga cagaagcccc 600ttgaagccta ggtagggcag gatcagagat acacccgtgt ttgtctcgaa gggctccaca 660gcccagtacg acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720cgcgaattta gtagtaatag cggccgc
Claims (22)
1、包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I调节一种或几种VEGF/VEGF受体系统的生物功能,所述化合物II调节一种或几种血管生成素/Tie受体系统的生物功能。
2、包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I通过一种或几种VEGF/VEGF受体系统靶向于内皮,所述化合物II调节一种或几种血管生成素/Tie受体系统的生物功能。
3、包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I调节一种或几种VEGF/VEGF受体系统的生物功能,或者调节一种或几种血管生成素/Tie受体系统的生物功能,所述化合物II靶向于内皮。
4、包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I调节一种或几种VEGF/VEGF受体系统的生物功能,所述化合物II通过一种或几种血管生成素/Tie受体系统靶向于内皮。
5、包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I通过一种或几种VEGF/VEGF受体系统靶向于内皮,所述化合物II通过一种或几种血管生成素/Tie受体系统靶向于内皮。
6、包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I调节一种或几种VEGF/VEGF受体系统的生物功能,所述化合物II通过一种或几种VEGF/VEGF受体系统靶向于内皮。
7、包含一种或几种试剂作为化合物I,以及一种或几种试剂作为化合物II的药物组合物,所述化合物I调节一种或几种血管生成素/Tie受体系统的生物功能,所述化合物II通过一种或几种血管生成素/Tie受体系统靶向于内皮。
8、包含一种或几种试剂的药物组合物,所述试剂既干扰一种或几种VEGF/VEGF受体系统的功能,也干扰一种或几种血管生成素/Tie受体系统的功能。
9、根据权利要求1-8的药物组合物,所述药物组合物打算供同时或单独顺序治疗施用。
10、根据权利要求1-8的药物组合物,所述药物组合物包含至少下列化合物之一作为化合物I:
a)抑制受体酪氨酸激酶活性的化合物;
b)抑制配体结合于受体的化合物;
c)抑制受体的胞内信号途径激活的化合物;
d)抑制或刺激VEGF或Tie受体系统的配体或受体表达的化
合物;
e)输运系统,如抗体、配体、高亲和性结合寡核苷酸或寡肽,
或脂质体,它们通过VEGF/VEGF受体系统或血管生成素
/Tie受体系统的识别使细胞毒试剂或凝固作用诱导试剂靶
向于内皮;
f)输运系统,如抗体、配体、高亲和性结合寡核苷酸或寡肽,
或脂质体,它们靶向于内皮并诱导坏死或凋亡。
11、根据权利要求1-8的药物组合物,所述药物组合物包含至少下列化合物之一作为化合物II:
g)抑制受体酪氨酸激酶活性的化合物;
h)抑制配体结合于受体的化合物;
i)抑制受体的胞内信号途径激活的化合物;
j)抑制或刺激VEGF或Tie受体系统的配体或受体表达的化 合物;
k)输运系统,如抗体、配体、高亲和性结合寡核苷酸或寡肽,
或脂质体,它们通过VEGF/VEGF受体系统或血管生成素
/Tie受体系统的识别使细胞毒试剂或凝固作用诱导试剂靶
向于内皮;
l)输运系统,如抗体、配体、高亲和性结合寡核苷酸或寡肽,
或脂质体,它们靶向于内皮并诱导坏死或凋亡。
12、根据权利要求1-11的药物组合物,所述药物组合物包含Seq.ID No.1-59中至少之一作为化合物I和/或II。
13、根据权利要求1-11的药物组合物,所述药物组合物包含Seq.ID No.34a作为化合物I和/或II。
14、根据权利要求1-11的药物组合物,所述药物组合物包含sTie2、mAB 4301-42-35、scFv-tTF和/或L19 scFv-tTF缀合物中至少之一作为化合物I和/或II。
15、根据权利要求1-11的药物组合物,所述药物组合物包含以下至少一种小分子作为化合物I和/或II:通式I的化合物,或者所述化合物的N氧化物,其中一个或多个N原子携带氧原子;或者是它们的盐,式中r为0至2,n为0至2;R3和R4 a)彼此独立地代表低级烷基;
c)一起形成通式III的桥,其中环成员T1、T2、T3、T4中的一个或两个代表氮,其它代表CH,并且通过原子T1和T4连接;G代表C1-C6烷基、C2-C6亚烷基或C2-C6亚烯基;或者被酰氧基或羟基取代的C2-C6亚烷基或C3-C6亚烯基;-CH2-O-、-CH2-S-、-CH2-NH-、-CH2-O-CH2-、-CH2-S-CH2-、-CH2-NH-CH2、氧(-O-)、硫(-S-)或亚氨基(-NH-);A、B、D、E和T彼此独立地代表N或CH,条件是这些取代基中不超过三个代表N;Q代表低级烷基、低级烷氧基或卤素;R1和R2彼此独立地代表H或低级烷基;X代表亚氨基、氧或硫;Y代表氢、未取代或取代的芳基、杂芳基,或者未取代或取代的环烷基;且Z代表氨基、单或二取代的氨基、卤素、烷基、取代的烷基、羟基、醚化或酯化的羟基、硝基、氰基、羧基、酯化的羧基、烷酰基、氨基甲酰基、N-单取代或N,N-二取代的氨基甲酰基、脒基、胍基、巯基、硫代、苯硫基、苯基-低级烷基-硫、烷基-苯基-硫、苯基亚磺酰基、苯基-低级烷基-亚磺酰基、烷基苯基亚磺酰基、苯基磺酰基、苯基-低级烷-磺酰基,或者烷基苯基磺酰基,但是,如果存在多于一个其余的Z(m≥2),取代基Z彼此相同或不同,而且其中箭头表示的键是单键或双键;和/或通式IV的化合物,以及它们的异构体和盐,式中A代表=NR2基团;W代表氧、硫、两个氢原子或=NR8基团,Z代表=NR10基团,或=N-、-N(R10)-、(CH2)q-、支链或非支链C1-6烷基,或者是以下基团:或者A、Z和R1一起形成以下基团: 或
m、n和o为0至3,q为1至6,Ra、Rb、Rc、Rd、Re、Rf彼此独立地代表氢、C1-4烷基或=NR10基团,和/或Ra和/或Rb与Rc和/或Rd一起,或者Rc与Re和/或Rf一起形成键,或者Ra-Rf基团中多达两个与R1或R2形成每个多达三个碳原子的桥,X代表=NR9或=N-基团;Y代表-(CH2)p基团,p为整数1至4;R1代表未取代或任选地被一个或多个卤素取代的C1-6烷基,或任选地被一个或多个卤素取代的C1-6烷基或C1-6烷氧基,或者是未取代或取代的芳基或杂芳基;R2代表氢或C1-6烷基,或与Ra-Rf和Z或R1一起形成多达3个环原子的桥;R3代表单环或双环芳基或杂芳基,它们未被取代或任选地被一个或多个卤素、C1-6烷基、C1-6烷氧基或羟基取代;R4、R5、R6和R7彼此独立地代表氢、卤素或C1-6烷氧基、C1-6烷基或C1-6羧基烷基,它们未被取代或任选地被一个或多个卤素取代,或者R5和R6一起形成以下基团:R8、R9和R10彼此独立地代表氢或C1-6烷基,和/或通式V的化合物,以及它们的异构体和盐,式中R1代表以下基团:式中R5是氯、溴或-OCH3基团,式中R7是-CH3或氯,式中R8是-CH3、氟、氯或 式中R4是 式中R6是-CH3-CF3, 氟、氯、溴、 或氯
-CF3、-N=C、
-CH3、-OCF3
16、根据权利要求15的药物组合物,所述药物组合物包含琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵作为化合物I和/或II。
17、根据权利要求1-16的药物组合物,所述药物组合物包含琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵、sTie2、mAB4301-42-35、scFv-tTF和/或L19 scFv-tTF缀合物作为化合物I,以及琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵、sTie2、mAB4301-42-35、scFv-tTF和/或L19 scFv-tTF缀合物作为化合物II,条件是化合物I与化合物II不同。
18、根据权利要求1-17的药物组合物,所述药物组合物包含琥珀酸(4-氯苯基)[4-(4-吡啶甲基)-酞嗪-1-基]氢铵作为化合物I,以及sTie2、mAB 4301-42-35、scFv-tTF和/或L19 scFv-tTF缀合物作为化合物II。
19、根据权利要求1-17的药物组合物,所述药物组合物包含mAB 4301-42-35作为化合物I,以及sTie2和/或scFv-tTF缀合物作为化合物II。
20、根据权利要求1-17的药物组合物,所述组合物包含scFv-tTF缀合物作为化合物I,以及sTie2和/或mAB 4301-42-35作为化合物II。
21、根据权利要求1-17的药物组合物,所述药物组合物包含L19 scFv-tTF缀合物作为化合物I,以及sTie2作为化合物II。
22、根据权利要求1-21的药物组合物用于生产药物的用途,所述药物用于治疗肿瘤、癌症、银屑病、关节炎如类风湿性关节炎、血管瘤、血管纤维瘤、眼病如糖尿病性视网膜病变、新生血管性青光眼、肾病如肾小球肾炎、糖尿病肾病、恶性肾硬化、血栓性微血管病综合征、移植排斥反应和肾小球病、纤维化疾病如硬变肝、肾小球膜细胞增生疾病、关节硬化、神经组织损伤、抑制患者中腹水形成和抑制VEGF水肿。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00250194A EP1166798A1 (en) | 2000-06-23 | 2000-06-23 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use |
EP00250194.8 | 2000-06-23 | ||
EP00250214A EP1166799A1 (en) | 2000-06-28 | 2000-06-28 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II) |
EP00250214.4 | 2000-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1479629A true CN1479629A (zh) | 2004-03-03 |
Family
ID=26072945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA018115837A Pending CN1479629A (zh) | 2000-06-23 | 2001-06-20 | 干扰VEGF/VEGF和血管生成素/Tie受体功能的组合和组合物以及它们的用途(II) |
Country Status (29)
Country | Link |
---|---|
US (2) | US20030055006A1 (zh) |
EP (2) | EP1292335B1 (zh) |
JP (1) | JP2003535910A (zh) |
KR (2) | KR20080068151A (zh) |
CN (1) | CN1479629A (zh) |
AT (1) | ATE363291T1 (zh) |
AU (1) | AU784231B2 (zh) |
BG (1) | BG107396A (zh) |
BR (1) | BR0111861A (zh) |
CA (1) | CA2411236A1 (zh) |
CY (1) | CY1107717T1 (zh) |
CZ (1) | CZ2003187A3 (zh) |
DE (1) | DE60128685T2 (zh) |
DK (1) | DK1292335T3 (zh) |
EE (1) | EE200200706A (zh) |
ES (1) | ES2287152T3 (zh) |
HR (1) | HRP20030041A2 (zh) |
HU (1) | HUP0302779A3 (zh) |
IL (1) | IL152794A0 (zh) |
ME (1) | MEP13708A (zh) |
MX (1) | MXPA02011897A (zh) |
NO (1) | NO20026152L (zh) |
NZ (1) | NZ536196A (zh) |
PL (1) | PL359653A1 (zh) |
PT (1) | PT1292335E (zh) |
RS (1) | RS50249B (zh) |
RU (1) | RU2292221C2 (zh) |
SK (1) | SK542003A3 (zh) |
WO (1) | WO2001097850A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102250248A (zh) * | 2011-06-15 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗vegf/ang2双特异性抗体及其应用 |
CN108546301A (zh) * | 2007-02-27 | 2018-09-18 | Aprogen株式会社 | 结合生长因子的融合蛋白 |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
EP2286843A3 (en) | 2000-06-02 | 2011-08-03 | Bracco Suisse SA | Compounds for targeting endothelial cells |
US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
WO2005078097A2 (en) | 2004-02-10 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA) |
AU2002314433A1 (en) * | 2001-07-02 | 2003-01-21 | Licentia Ltd. | Ephrin-tie receptor materials and methods |
US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1432724A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7985402B2 (en) | 2002-03-01 | 2011-07-26 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
US20050250700A1 (en) * | 2002-03-01 | 2005-11-10 | Sato Aaron K | KDR and VEGF/KDR binding peptides |
EP1587944A4 (en) | 2002-03-01 | 2007-03-21 | Dyax Corp | KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US7666979B2 (en) | 2002-03-01 | 2010-02-23 | Bracco International B.V. | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same |
US20060228706A1 (en) * | 2002-06-04 | 2006-10-12 | Metabolex, Inc. | Methods of diagnosing and treating diabetes and insulin resistance |
GB0222276D0 (en) * | 2002-09-25 | 2002-10-30 | Inst Of Molecul & Cell Biology | Methods |
DK2949658T3 (en) | 2003-03-03 | 2018-10-01 | Dyax Corp | Peptides that specifically bind HGF receptor (cMet) and uses thereof |
JP2006523464A (ja) * | 2003-04-18 | 2006-10-19 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | アンジオポエチン1、2、及びそれらの受容体TIE2のsiRNA阻害のための組成物及びその方法 |
US7485297B2 (en) * | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
US7871610B2 (en) * | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
WO2005019267A2 (en) * | 2003-08-12 | 2005-03-03 | Dyax Corp. | Tie1-binding ligands |
EP1732947B1 (en) | 2004-03-05 | 2011-04-27 | Vegenics Pty Ltd | Growth factor binding constructs materials and methods |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
SI1771474T1 (sl) * | 2004-07-20 | 2010-06-30 | Genentech Inc | Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba |
US20060105663A1 (en) * | 2004-10-04 | 2006-05-18 | Stefan Greulich | Polymer assemblies with decorative surfaces |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
US8926945B2 (en) | 2005-10-07 | 2015-01-06 | Guerbet | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium |
CA2633211A1 (en) | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
KR101589391B1 (ko) | 2006-01-05 | 2016-01-29 | 제넨테크, 인크. | 항-ephb4 항체 및 그의 사용 방법 |
AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
CA2647430A1 (en) * | 2006-03-29 | 2007-10-11 | Genentech, Inc. | Diagnostics and treatments for tumors |
NZ571300A (en) | 2006-04-07 | 2011-12-22 | Warner Chilcott Co Llc | Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof |
AU2007319672B2 (en) * | 2006-06-06 | 2011-06-30 | Genentech, Inc. | Anti-DLL4 antibodies and methods using same |
TW200817435A (en) * | 2006-06-06 | 2008-04-16 | Genentech Inc | Compositions and methods for modulating vascular development |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US20080213253A1 (en) * | 2007-01-12 | 2008-09-04 | Dyax Corp. | Combination therapy for the treatment of cancer |
US20100119526A1 (en) * | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
AU2008324789A1 (en) | 2007-11-09 | 2009-05-14 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist compositions and methods of use |
AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
KR20110015516A (ko) | 2008-03-14 | 2011-02-16 | 옵셰스트보 스 오그라니첸노이 오트베츠벤노스티유 "이니티움-파름" | 혈관신생억제 작용을 갖는 항종양 테르페노이드 약학적 조성물 ‘아비실린’ |
KR20110068987A (ko) * | 2008-08-29 | 2011-06-22 | 제넨테크, 인크. | Vegf-비의존적 종양의 진단 및 치료 |
PE20110707A1 (es) | 2008-10-14 | 2011-10-11 | Genentech Inc | Variantes de inmunoglobulinas |
EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
FR2942227B1 (fr) | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
DK2451279T3 (da) | 2009-07-06 | 2019-05-20 | Aerpio Therapeutics Inc | Benzosulfonamid derivater forbindelser deraf og deres brug til at forhindre metastaser af cancerceller |
EP2459591B1 (en) * | 2009-07-31 | 2014-08-20 | Genentech, Inc. | Inhibition of tumor metastasis using anti-g-csf-antibodies |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056997A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
ES2565208T3 (es) | 2009-12-11 | 2016-04-01 | F. Hoffmann-La Roche Ag | Anticuerpos anti-VEGF-C y métodos de uso de los mismos |
CN103068849B (zh) | 2009-12-23 | 2016-04-06 | 霍夫曼-拉罗奇有限公司 | 抗Bv8抗体及其用途 |
ES2663009T3 (es) | 2010-10-29 | 2018-04-10 | Sirna Therapeutics, Inc. | Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic) |
JP5945277B2 (ja) | 2010-11-15 | 2016-07-05 | ファイブ プライム セラピューティックス インコーポレイテッド | Fgfr1細胞外ドメイン併用療法 |
FR2968999B1 (fr) | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
CN108341863A (zh) | 2011-04-20 | 2018-07-31 | 阿塞勒隆制药公司 | 内皮糖蛋白多肽及其用途 |
MX2014001736A (es) | 2011-08-17 | 2014-03-31 | Genentech Inc | Inhibicion de angiogenesis en tumores refractarios. |
AU2012299195B9 (en) | 2011-08-19 | 2018-05-10 | Regeneron Pharmaceuticals, Inc | Anti-Tie2 antibodies uses thereof |
US10316105B2 (en) | 2011-08-19 | 2019-06-11 | Regeneron Pharmaceuticals, Inc. | Anti-TIE2 antibodies and uses thereof |
FR2980364B1 (fr) | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
ES2774972T3 (es) | 2011-10-13 | 2020-07-23 | Aerpio Therapeutics Inc | Tratamiento de enfermedades oculares |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
FR3001154B1 (fr) | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
KR20220013459A (ko) | 2013-10-25 | 2022-02-04 | 악셀레론 파마 인코포레이티드 | 섬유화 질환을 치료하기 위한 엔도글린 펩티드 |
US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
US10253094B2 (en) | 2016-07-20 | 2019-04-09 | Aerpio Therapeutics, Inc. | Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions |
AU2017315075B2 (en) | 2016-08-23 | 2020-10-01 | Medimmune Limited | Anti-VEGF-A and anti-ANG2 antibodies and uses thereof |
WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
-
2001
- 2001-06-20 IL IL15279401A patent/IL152794A0/xx unknown
- 2001-06-20 PT PT01965012T patent/PT1292335E/pt unknown
- 2001-06-20 HU HU0302779A patent/HUP0302779A3/hu unknown
- 2001-06-20 SK SK54-2003A patent/SK542003A3/sk unknown
- 2001-06-20 KR KR1020087016915A patent/KR20080068151A/ko not_active Application Discontinuation
- 2001-06-20 RU RU2003100502/15A patent/RU2292221C2/ru not_active IP Right Cessation
- 2001-06-20 EE EEP200200706A patent/EE200200706A/xx unknown
- 2001-06-20 EP EP01965012A patent/EP1292335B1/en not_active Expired - Lifetime
- 2001-06-20 CA CA002411236A patent/CA2411236A1/en not_active Abandoned
- 2001-06-20 NZ NZ536196A patent/NZ536196A/en unknown
- 2001-06-20 BR BR0111861-7A patent/BR0111861A/pt not_active IP Right Cessation
- 2001-06-20 CN CNA018115837A patent/CN1479629A/zh active Pending
- 2001-06-20 DK DK01965012T patent/DK1292335T3/da active
- 2001-06-20 KR KR1020027017482A patent/KR20030036238A/ko not_active Application Discontinuation
- 2001-06-20 ME MEP-137/08A patent/MEP13708A/xx unknown
- 2001-06-20 DE DE60128685T patent/DE60128685T2/de not_active Expired - Fee Related
- 2001-06-20 AU AU85766/01A patent/AU784231B2/en not_active Ceased
- 2001-06-20 ES ES01965012T patent/ES2287152T3/es not_active Expired - Lifetime
- 2001-06-20 PL PL01359653A patent/PL359653A1/xx unknown
- 2001-06-20 AT AT01965012T patent/ATE363291T1/de not_active IP Right Cessation
- 2001-06-20 WO PCT/EP2001/006976 patent/WO2001097850A2/en active IP Right Grant
- 2001-06-20 RS YU97202A patent/RS50249B/sr unknown
- 2001-06-20 CZ CZ2003187A patent/CZ2003187A3/cs unknown
- 2001-06-20 JP JP2002503334A patent/JP2003535910A/ja active Pending
- 2001-06-20 EP EP05090011A patent/EP1586333A2/en not_active Withdrawn
- 2001-06-20 MX MXPA02011897A patent/MXPA02011897A/es active IP Right Grant
- 2001-06-25 US US09/887,527 patent/US20030055006A1/en not_active Abandoned
-
2002
- 2002-12-17 BG BG107396A patent/BG107396A/bg unknown
- 2002-12-20 NO NO20026152A patent/NO20026152L/no not_active Application Discontinuation
-
2003
- 2003-01-23 HR HR20030041A patent/HRP20030041A2/hr not_active Application Discontinuation
-
2004
- 2004-03-10 US US10/796,174 patent/US20040147449A1/en not_active Abandoned
-
2007
- 2007-08-14 CY CY20071101085T patent/CY1107717T1/el unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108546301A (zh) * | 2007-02-27 | 2018-09-18 | Aprogen株式会社 | 结合生长因子的融合蛋白 |
CN108546301B (zh) * | 2007-02-27 | 2021-09-07 | Aprogen株式会社 | 结合生长因子的融合蛋白 |
CN102250248A (zh) * | 2011-06-15 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗vegf/ang2双特异性抗体及其应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1479629A (zh) | 干扰VEGF/VEGF和血管生成素/Tie受体功能的组合和组合物以及它们的用途(II) | |
US11939384B1 (en) | Antibody variable domains targeting the NKG2D receptor | |
KR102691790B1 (ko) | 항-pd-l1/vegf 이중 기능 항체 및 이의 용도 | |
CN1200734C (zh) | 用表皮生长因子拮抗物治疗顽固性的人肿瘤 | |
JP2024023438A (ja) | 多重特異性結合タンパク質及びその改善 | |
US9409990B2 (en) | Methods of inhibiting tumor growth by antagonizing IL-6 receptor | |
US20210221894A1 (en) | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams | |
JP6978409B2 (ja) | 抗tf抗体薬物コンジュゲートの投薬レジメン | |
CN105611944A (zh) | 抗ang2抗体和cd40激动剂的组合疗法 | |
AU2018318698A1 (en) | Proteins binding NKG2D, CD16, and EGFR, HLA-E CCR4, or PD-L1 | |
JP2020507328A (ja) | Bcma、nkg2d及びcd16と結合するタンパク質 | |
JP6587756B2 (ja) | 免疫毒素およびチェックポイント阻害剤の併用療法 | |
JP2014500278A (ja) | 二重特異性scFvコンジュゲートの投薬量および投与 | |
JP2020510039A5 (zh) | ||
JP2023522972A (ja) | ヘテロ二量体Fc融合タンパク質のための製剤、投薬量レジメン、及び製造工程 | |
CN112437672A (zh) | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 | |
CN1416432A (zh) | Cd25结合分子在治疗胃肠道炎性疾病中的用途 | |
EP1166799A1 (en) | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II) | |
EP1166798A1 (en) | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use | |
US12129300B2 (en) | Antibody variable domains targeting the NKG2D receptor | |
RU2788531C2 (ru) | Белок, связывающийся с nkg2d, cd16 и с опухолеспецифическим антигеном | |
RU2816716C2 (ru) | Белки, связывающие NKG2D, CD16 и опухолеассоциированный антиген | |
RU2805254C2 (ru) | Белки, связывающие всма, nkg2d и cd16 | |
EA043960B1 (ru) | Антигенсвязывающие сайты, которые связываются с рецептором 2d группы естественных киллеров | |
CN1720994A (zh) | 用表皮生长因子受体拮抗物治疗顽固性的人肿瘤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1063730 Country of ref document: HK |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1063730 Country of ref document: HK |